var docs;if (!docs) docs =[]; docs["65"]={"6500":"<p><b>Title</b> Mercaptopurine / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor immune function and hematologic status closely in patients receiving mercaptopurine who are also given trimethoprim.</p> \n<p><b>Discussion</b> Various reports have described excessive leukopenia associated with use of sulfamethoxazole-trimethoprim (SMZ/TMP) in patients receiving azathioprine, a drug that is in part metabolized to mercaptopurine.<sup>1,2</sup> One report noted that 6 renal transplant recipients who were given both SMZ/TMP and azathioprine experienced neutropenia and thrombocytopenia at a higher incidence and of longer duration than 25 similar patients who received azathioprine without SMZ/TMP.<sup>2</sup> Another report describes a similar severe leukopenia associated with use of trimethoprim together with azathioprine.<sup>3</sup> Of note, an observational study found that patients receiving azathioprine together with SMZ/TMP experienced no more hematologic toxicity than those receiving azathioprine together with another antibiotic.<sup>4</sup><br><br>The mechanism of this purported interaction is enhancement of 6-mercaptopurine (active moiety of azathioprine) bone marrow suppression by the antifolate actions of TMP/SMZ.<sup>2</sup> Case reports and data from cross-sectional and case-report studies support such an interaction, suggesting that SMZ/TMP can cause hematologic toxicity (independent of any combination with azathioprine).<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hulme B, Reeves DS, “Leucopenia Associated with Trimethoprim-Sulphamethoxazole after Renal Transplantation,” <i>Br Med J</i>, 1971, 3:610-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4936539\">[PubMed 4936539]</a></p>\n<p>2. Bradley PP, Warden GD, Maxwell JG, et al, “Neutropenia and Thrombocytopenia in Renal Allograft Recipients Treated with Trimethoprim-Sulfamethoxazole,” <i>Ann Intern Med</i>, 1980, 93:560-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7001973\">[PubMed 7001973]</a></p>\n<p>3. Bailey RR, “Leukopenia Due to a Trimethoprim-Azathioprine Interaction,” <i>N Z Med J</i>, 1984, 97:739. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6595562\">[PubMed 6595562]</a></p>\n<p>4. Hall CL, “Co-Trimoxazole and Azathioprine: A Safe Combination,” <i>Br Med J</i>, 1974, 4:15-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4609544\">[PubMed 4609544]</a></p>\n<p>5. Andres E, Noel E, Maloisel F, “Trimethoprim-Sulfamethoxazole-Induced Life-Threatening Agranulocytosis,” <i>Arch Intern Med</i>, 2003, 163(16):1975-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12963573\">[PubMed 12963573]</a></p>\n<p>6. van der Klauw MM, Goudsmit R, Halie MR, et al, “A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis,” <i>Arch Intern Med</i>, 1999, 159(4):369-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10030310\">[PubMed 10030310]</a></p>\n<p>7. van der Klauw MM, Wilson JH, Stricker BH, “Drug-Associated Agranulocytosis: 20 Years of Reporting in The Netherlands (1974-1994),” <i>Am J Hematol</i>, 1998, 57(3):206-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9495370\">[PubMed 9495370]</a></p>\n<p>8. Myers MW, Jick H, “Hospitalization for Serious Blood and Skin Disorders Following Co-Trimoxazole,” <i>Br J Clin Pharmacol</i>, 1997, 43(6):649-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9205827\">[PubMed 9205827]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6501":"<p><b>Title</b> Vardenafil / Clarithromycin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Clinical action rating appears dependent on specific product used. Labeling recommendations vary between dose reduction and avoidance of concomitant use.</p></li>\n <li><p><b>International labeling</b>: Recommendations may vary between international labelings.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Vardenafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations regarding the concomitant use of vardenafil and clarithromycin vary between international labelings and between commercially available vardenafil brand name products (Levitra, Staxyn). In the U.S., Levitra product labeling recommends limiting the vardenafil dose to 2.5 mg/24-hour period when used with clarithromycin,<sup>1</sup> while Staxyn product labeling recommends avoiding concomitant use with clarithromycin.<sup>2</sup> In Canada, Levitra product monograph recommends limiting the vardenafil dose to 5 mg/24-hour period with concomitant clarithromycin,<sup>3</sup> while Staxyn product monograph contraindicates concomitant use with clarithromycin.<sup>4</sup><br> <br>Monitor closely for evidence of vardenafil toxicity in patients receiving concomitant clarithromycin.</p> \n<p><b>Discussion</b> When used with the moderate CYP3A4 inhibitor erythromycin (500 mg three times/day), the average vardenafil AUC was 4-fold higher, while with stronger CYP3A4 inhibitors (e.g., ritonavir, indinavir, higher-dose ketoconazole or itraconazole), the average vardenafil AUC was increased by up to 16- to 49-fold higher.<sup>1</sup> The mechanism of this interaction appears to be inhibition of the CYP3A-mediated metabolism of vardenafil. Clarithromycin, a potent CYP3A4 inhibitor as well, would similarly be expected to inhibit vardenafil metabolism.<br><br>In the U.S., vardenafil is available as film-coated tablets (Levitra) and orally disintegrating tablets (Staxyn). Following administration of Staxyn (10 mg), mean vardenafil AUC increased 44% in healthy men and 21-29% in men with erectile dysfunction, when compared to Levitra (10 mg).<sup>2</sup> At equivalent doses, it might therefore seem reasonable to anticipate interactions of greater magnitude between Staxyn and drugs such as clarithromycin which inhibit vardenafil metabolism. Recommendations regarding the concomitant use of vardenafil and clarithromycin vary between international labelings and between commercially available vardenafil brand name products. In the U.S., Levitra product labeling recommends limiting the vardenafil dose to 2.5 mg/24-hour period when used with clarithromycin,<sup>1</sup> while Staxyn product labeling recommends avoiding concomitant use with clarithromycin.<sup>2</sup> In Canada, Levitra product monograph recommends limiting the vardenafil dose to 5 mg/24-hour period with concomitant clarithromycin,<sup>3</sup> while Staxyn product monograph contraindicates concomitant use with clarithromycin.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Levitra (vardenafil). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 4/2011.</p>\n<p>2. Prescribing information. Staxyn (vardenafil). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 8/2010.</p>\n<p>3. Product monograph. Levitra (vardenafil). Toronto, Ontario: Bayer Inc., 7/2011.</p>\n<p>4. Product monograph. Staxyn (vardenafil). Toronto, Ontario: Bayer Inc., 8/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6502":"<p><b>Title</b> Bortezomib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of any strong CYP3A4 inducer in patients being treated with bortezomib. Of note, dexamethasone is described as only a weak inducer of CYP3A4 in the bortezomib prescribing information, implying that this recommendation does not apply to dexamethasone.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> According to bortezomib prescribing information, bortezomib exposure was reduced by an average of 45% with concurrent use of the strong CYP3A inducer rifampin.<sup>1</sup> Though details of the study are not described, it is noted that the study was small (n=6) and not designed to evaluate the maximum potential effect of concurrent rifampin, leading the prescribing information to state that the described 45% reduction in bortezomib exposure should be considered more of a minimum expected effect. As a result of these findings and the potential negative impact on bortezomib effectiveness, concurrent use of any strong CYP3A4 inducers with bortezomib is not recommended.<sup>1</sup><br><br>In contrast, the prescribing information also states that concurrent use of bortezomib with dexamethasone, which is often classified as a strong CYP3A4 inducer but is classified as only a weak inhibitor in the bortezomib prescribing information, was not associated with any significant change in bortezomib exposure (n=7).<sup>1</sup> Due to the prescribing information's classification of dexamethasone as a “weak” CYP3A4 inducer, the recommendation to avoid concurrent use with bortezomib does not appear to extend to dexamethasone.<br><br>The mechanism for this apparent interaction appears to be increased bortezomib metabolism (and decreased exposure) due to the CYP3A4-inducing effects of rifampin and other similar strong CYP3A4 inducers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Velcade (bortezomib). Cambridge, MA: Millennium Pharmaceuticals, Inc., 11/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6503":"<p><b>Title</b> Bortezomib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Bortezomib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of St Johns Wort in patients being treated with bortezomib.</p> \n<p><b>Discussion</b> The strong CYP3A inducer rifampin has been shown to reduce bortezomib exposure by at least 45% in one small study summarized in the bortezomib prescribing information, and given the variable enzyme-inducing potential of St Johns Wort, concurrent use of St Johns Wort with bortezomib should be avoided.<sup>1</sup><br><br>The mechanism for this expected interaction is St Johns Wort-mediated induction of bortezomib metabolism, leading to reduced bortezomib concentrations and potentially to reduced clinical effectiveness.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Velcade (bortezomib). Cambridge, MA: Millennium Pharmaceuticals, Inc., 11/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6504":"<p><b>Title</b> CloZAPine / Myelosuppressive Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of neutropenia (ie, decreased absolute neutrophil count [ANC]) when taking clozapine and another myelosuppressive agent. Monitor ANC more often than is recommended for usual clozapine use.</p>\n<div>\n <p><b>Myelosuppressive Agents Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Aldesleukin, Alemtuzumab, Altretamine, Amsacrine, Arsenic Trioxide, AzaCITIDine, Belinostat, Belotecan, Bendamustine, Bevacizumab, Bexarotene (Systemic), Blinatumomab, Bortezomib, Bosutinib, Busulfan, Cabazitaxel, Capecitabine, CarBAMazepine, Carbimazole, CARBOplatin, Carfilzomib, Carmustine, Chlorambucil, Chloramphenicol (Ophthalmic), Chloramphenicol (Systemic), CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, Daratumumab, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, Dexrazoxane, Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Edetate CALCIUM Disodium, EpiRUBicin, EriBULin, Etoposide, Etoposide Phosphate, Everolimus, Floxuridine, Flucytosine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Inotuzumab Ozogamicin, Interferon Alfa-2a, Interferon Alfa-2b, Interferon Alfa-n3, Interferon Alfacon-1, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Ixazomib, Lenalidomide, Linezolid, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, MethIMAzole, Methotrexate, Midostaurin, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Nilotinib, Niraparib, Obinutuzumab, Olaparib, Olaratumab, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Peginterferon Alfa-2a, Peginterferon Alfa-2b, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PONATinib, Procarbazine, Propylthiouracil, Radium Ra 223 Dichloride, Radotinib, Raltitrexed, Ribociclib, RiTUXimab, RomiDEPsin, Rucaparib, Ruxolitinib, Sirolimus, SORAfenib, Streptozocin, Tacrolimus (Systemic), Tedizolid, Tegafur, Temozolomide, Temsirolimus, Teniposide, Thalidomide, Thioguanine, Thiotepa, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Trifluridine and Tipiracil, Venetoclax, VinBLAStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine, Vorinostat, Zidovudine, Ziv-Aflibercept (Systemic)</p>\n</div> \n<p><b>Discussion</b> Use of clozapine is independently associated with a significant risk for neutropenia, which is a serious and potentially life-threatening toxicity. It is unclear if concurrent use of other drugs known to cause neutropenia increases the risk or severity of clozapine-induced neutropenia. If clozapine is used concurrently with an agent known to cause neutropenia consider monitoring patients more closely than the standard clozapine treatment guidelines suggest.<sup>1</sup> Consult with the treating oncologist in patients receiving concomitant chemotherapy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6505":"<p><b>Title</b> Dabigatran Etexilate / Ketoconazole (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, and country-specific labeling recommendations. <br><br>In patients with normal renal function (CrCl greater than 50 mL/min), the combination of dabigatran etexilate and systemic ketoconazole should be used with extra caution, monitoring patients closely for signs/symptoms of bleeding. In patients using dabigatran for atrial fibrillation with moderately impaired renal function (CrCl 30-50 mL/min), the U.S. prescribing information recommends using a lower dabigatran etexilate dose (75 mg twice/day) when used in combination with systemic ketoconazole. In patients with severe renal function impairment (CrCl 15-30 mL/min), concurrent use of dabigatran etexilate with any P-glycoprotein inhibitor (such as ketoconazole) should be avoided. In patients using dabigatran for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) with moderate renal dysfunction (CrCl 30-50 ml/min), the combination of dabigatran etexilate with any P-glycoprotein inhibitor (such as ketoconazole) should be avoided. Some non-US labeling for dabigatran etexilate contraindicates concurrent use of oral ketoconazole (regardless of renal function).</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of the ketoconazole (both a strong CYP3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor) was not associated with a significant increase in the risk for major bleeding.<sup>1</sup> Several other examined combinations in this cohort study also yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>Per data in the dabigatran etexilate U.S. prescribing information, concurrent use of dabigatran etexilate with single-dose ketoconazole (400 mg) was associated with a 138% increase in dabigatran etexilate AUC and a 135% increase in dabigatran etexilate maximum serum concentration (Cmax); with multiple doses of ketoconazole the increases in dabigatran etexilate AUC and Cmax were 153% and 149%, respectively.<sup>2</sup><br><br>Considering that dabigatran etexilate is a P-gp substrate and that ketoconazole is an inhibitor of P-gp, ketoconazole inhibition of dabigatran etexilate efflux is the likely mechanism for this interaction. Since P-gp-mediated efflux and renal elimination represent the primary means of dabigatran elimination, the magnitude of any P-gp related interaction may be greater in patients with diminished renal function. The Canadian product monograph for dabigatran etexilate contraindicates concurrent use of oral ketoconazole (regardless of renal function).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>3. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6507":"<p><b>Title</b> Dabigatran Etexilate / Dronedarone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those with atrial fibrillation receiving prophylaxis vs. those being treated for deep venous thrombosis or pulmonary embolism.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n <li><p><b>Renal Function</b>: The clinical significance and recommended management of this interaction both increase considerably in patients with moderate (CrCl 30-50 mL/min) or severe (CrCl 15-30 mL/min) renal dysfunction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dronedarone may increase the serum concentration of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The recommendations for management of this potential drug interaction depend on the indication for dabigatran use, patient renal function, and country specific labeling recommendations.<br><br>In patients with normal renal function (CrCl greater than 50 mL/min), the combination of dabigatran etexilate and dronedarone should be used with extra caution, monitoring patients closely for signs/symptoms of bleeding. In patients using dabigatran for atrial fibrillation with moderately impaired renal function (CrCl 30-50 mL/min), the U.S. prescribing information recommends using a lower dabigatran etexilate dose (75 mg twice/day) when used in combination with dronedarone. In patients with severe renal function impairment (CrCl 15-30 mL/min), concurrent use of dabigatran etexilate with any P-glycoprotein inhibitor (such as dronedarone) should be avoided. In patients using dabigatran for the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) with moderate renal dysfunction (CrCl 30-50 mL/min), the combination of dabigatran etexilate with any P-glycoprotein inhibitor (such as dronedarone) should be avoided. Some non-US labeling for dabigatran etexilate recommends avoiding concomitant use with dronedarone (regardless of renal function) and also contraindicates dabigatran use in severe renal dysfunction (CrCl less than 30 mL/min), regardless of any concurrent medications.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of the dronedarone (both a moderate CYP3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor) was not associated with a significant increase in the risk for major bleeding.<sup>1</sup> Several other examined combinations in this cohort study also yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>According to data in the dabigatran etexilate U.S. prescribing information, the mean dabigatran etexilate exposure was 73% to 99% higher with concurrent dronedarone.<sup>2</sup> Considering that dabigatran etexilate is a P-gp substrate and that dronedarone is an inhibitor of P-gp, dronedarone inhibition of dabigatran etexilate efflux is the likely mechanism for this interaction. Since P-gp-mediated efflux and renal elimination represent the primary means of dabigatran elimination, the magnitude of any P-gp related interaction may be greater in patients with diminished renal function.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>3. Pradaxa (dabigatran etexilate). [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6509":"<p><b>Title</b> CycloSPORINE (Systemic) / Colesevelam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colesevelam may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer cyclosporine at least 4 hours prior to colesevelam. Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.</p> \n<p><b>Discussion</b> In a drug interaction study described in colesevelam prescribing information, concurrent administration of colesevelam (3.75 g) decreased cyclosporine (200 mg) maximum concentration and AUC by 44% and 34%, respectively.<sup>1</sup> <br><br>The presumed primary mechanism of this interaction is colesevelam binding to cyclosporine in the gastrointestinal tract, thereby decreasing cyclosporine absorption. Although the impact of separating cyclosporine and colesevelam doses has not been investigated, colesevelam prescribing information recommends dosing cyclosporine at least 4 hours prior to colesevelam to minimize the potential for this interaction.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Welchol (colesevelam). Parsippany, NJ: Daiichi Sankyo, Inc, 7/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6510":"<p><b>Title</b> Ruxolitinib / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Based on US labeling, strong CYP3A4 inhibitors should be avoided in patients receiving ruxolitinib doses of 5 mg daily.</p></li>\n <li><p><b>Laboratory/Diagnostic Result</b>: Based on US labeling, initiation of ruxolitinib for treatment of myelofibrosis should be avoided in patients with platelet counts less than 50*10<sup>9</sup>/L receiving strong CYP3A4 inhibitors.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> <u>Based on ruxolitinib US labeling</u>: In adult patients receiving strong CYP3A4 inhibitors, initiate ruxolitinib for treatment of polycythemia vera at a dose of 5 mg twice daily. In patients receiving strong CYP3A4 inhibitors, initiate ruxolitinib for treatment of myelofibrosis at a dose of 10 mg twice daily in those with platelet counts 100*10<sup>9</sup>/L or greater, or 5 mg twice daily in those with platelet counts between 50*10<sup>9</sup>/L and 100*10<sup>9</sup>/L. In patients receiving established ruxolitinib doses, reduce ruxolitinib dose by 50% (rounded up to the nearest available tablet strength) if the previous dose was 10 mg twice daily or more, or reduce the dose to 5 mg once daily if the previous dose was 5 mg twice daily, following strong CYP3A4 inhibitor initiation. Avoid strong CYP3A4 inhibitors in patients receiving established ruxolitinib doses of 5 mg daily. <u>Based on ruxolitinib Canadian labeling</u>: Reduce ruxolitinib dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in ruxolitinib US prescribing information, coadministration of ketoconazole (200 mg twice daily for 4 days) increased the maximum concentration and AUC of ruxolitinib (10 mg single oral dose) in healthy volunteers by 33% and 91%, respectively.<sup>1,2</sup> A proportional, 2 fold increase in total interleukin-6-stimulated STAT3 phosphorylation was seen as well.<sup>2</sup> The presumed primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated ruxolitinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Jakafi</i> (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; December 2014.</p>\n<p>2. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21602517\">[PubMed 21602517]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6511":"<p><b>Title</b> Ruxolitinib / Grapefruit Juice</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Grapefruit juice should be avoided in patients receiving ruxolitinib doses of 5 mg daily.</p></li>\n <li><p><b>Laboratory/Diagnostic Result</b>: Initiation of ruxolitinib for treatment of myelofibrosis should be avoided in patients with platelet counts less than 50*10<sup>9</sup>/L consuming grapefruit juice.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Ruxolitinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of grapefruit juice with ruxolitinib when possible, and advise patients to avoid this (particularly consistent consumption of large volumes). In adult patients consuming grapefruit juice, initiate ruxolitinib for treatment of polycythemia vera at a dose of 5 mg twice daily. In patients consuming grapefruit juice, initiate ruxolitinib for treatment of myelofibrosis at a ruxolitinib dose of 10 mg twice daily in patients with platelet counts 100*10<sup>9</sup>/L or greater, or 5 mg twice daily in those with platelet counts between 50*10<sup>9</sup>/L and 100*10<sup>9</sup>/L. In patients receiving established ruxolitinib doses, reduce ruxolitinib dose by 50% (rounded up to the nearest available tablet strength) if the previous dose was 10 mg twice daily or more, or reduce the dose to 5 mg once daily if the previous dose was 5 mg twice daily, following grapefruit juice initiation. Grapefruit juice should be avoided in patients receiving established ruxolitinib doses of 5 mg daily.</p> \n<p><b>Discussion</b> In a clinical study summarized in ruxolitinib prescribing information, coadministration of ketoconazole (200 mg twice daily for 4 days) increased maximum concentration and AUC of ruxolitinib (10 mg single oral dose) in healthy volunteers by 33% and 91%, respectively.<sup>1,2</sup> A proportional, 2 fold increase in total interleukin-6-stimulated STAT3 phosphorylation was seen as well.<sup>2</sup> The presumed primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated ruxolitinib metabolism. Similar results could theoretically occur with consistent grapefruit juice intake (particularly large volumes) in combination with ruxolitinib.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Jakafi</i> (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; December 2014.</p>\n<p>2. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21602517\">[PubMed 21602517]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6512":"<p><b>Title</b> Itraconazole / Nevirapine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nevirapine may decrease the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The use of itraconazole concurrently with or within 2 weeks of nevirapine is not recommended. If this combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to itraconazole.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministration of nevirapine (200 mg daily for 7 days) decreased itraconazole (200 mg daily for 7 days) maximum concentration and AUC by 38% and 61%, respectively.<sup>1</sup> The most likely primary mechanism of this interaction is nevirapine induction of CYP3A4 mediated itraconazole metabolism. US prescribing information for both nevirapine and itraconazole recommends avoiding their concomitant use.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. <i>Eur J Clin Pharmacol</i>. 2007;63(5):451-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17342480\">[PubMed 17342480]</a></p>\n<p>2. Viramune (nevirapine) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2017.</p>\n<p>3. Sporanox (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6513":"<p><b>Title</b> Boceprevir / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of boceprevir with strong CYP3A4 inducers is contraindicated due to the risk for reduced boceprevir concentrations and clinical response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Boceprevir prescribing information contraindicates coadministration with strong CYP3A4 inducers, due to a potential risk for decreased boceprevir concentrations and therapeutic effects.<sup>1</sup> The presumed mechanism of this interaction is induction of CYP3A4-mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 02/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6518":"<p><b>Title</b> Cholinergic Agonists / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer these agents in combination with caution, and monitor for signs and symptoms of cardiac conduction disturbances. Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p><b>Cholinergic Agonists Interacting Members</b> Acetylcholine, Bethanechol, Carbachol, Cevimeline, Choline Alfoscerate, Guanidine, Methacholine, Pilocarpine (Ophthalmic), Pilocarpine (Systemic)</p>\n</div> \n<p><b>Discussion</b> Prescribing information for some cholinergic agonists (pilocarpine, cevimeline) warns that these agents should be administered with caution in patients receiving beta adrenergic antagonists, due to a potential for cardiac conduction disturbances.<sup>1,2</sup> Methacholine should not be used in patients receiving beta blockers due to the potential for additive bronchoconstrictive effects.<sup>3</sup> <br><br>These effects are anticipated due to the combined actions of increasing cholinergic activity and decreasing beta adrenergic activity in affected tissues (heart, lungs).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Evoxac (cevimeline). Edison, NJ: Daiichi Sankyo, Inc., 11/2006.</p>\n<p>2. Prescribing information. Pilocarpine. Philadelphia, PA: Global Pharmaceuticals, 4/2005.</p>\n<p>3. Prescribing Information. Provocholine (methacholine). Brantford, Ontario, Canada: Methapharm Inc., September 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6519":"<p><b>Title</b> Levothyroxine / Chromium</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only anticipated with oral administration of both agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Chromium may decrease the serum concentration of Levothyroxine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 7 euthyroid, healthy volunteers, simultaneous coadministration of chromium picolinate (1 mg) with levothyroxine (1 mg) decreased the AUC of serum T4 by 17%.<sup>1</sup> The mechanism of this interaction has not been investigated, but may involve formation of an insoluble or poorly-soluble chromium-levothyroxine complex in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. John-Kalarickal J, Pearlman G and Carlson HE, “New Medications Which Decrease Levothyroxine Absorption,” <i>Thyroid</i>, 2007, 17(9):763-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17725434\">[PubMed 17725434]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6520":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, discontinue selective serotonin reuptake inhibitors (SSRIs) prior to administration of linezolid. Waiting at least 2 weeks (5 weeks for fluoxetine) after SSRI discontinuation to initiate linezolid should minimize the interaction risk. If more urgent initiation of linezolid is needed, the availability of alternative agents and interventions should be considered. If the benefit of linezolid under such circumstances outweighs the risk of serotonin toxicity, discontinue the SSRI immediately and monitor closely for signs of CNS toxicity for 2 weeks (3 weeks for vortioxetine, 5 weeks for fluoxetine) after the last SSRI dose, or 24 hours after the last dose of linezolid, whichever comes first. SSRI treatment may be resumed 24 hours after the last dose of linezolid. Initiation of an SSRI during linezolid treatment is considered contraindicated.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al. Linezolid and serotonin syndrome. <i>Psychosomatics</i>. 2001;42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. <i>Clin Infect Dis</i>. 2002;34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. <i>Clin Infect Dis</i>. 2003;36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. <i>Clin Infect Dis</i>. 2003;37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram. <i>J Am Med Dir Assoc</i>. 2004;5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al. Serotonin syndrome and linezolid. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. <i>Ann Pharmacother</i>. 2005;39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. <i>Psychosomatics</i>. 2005;46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. <i>J Intensive Care Med</i>. 2005;20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. <i>Pharmacotherapy</i>. 2006;26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al. Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. <i>Mayo Clin Proc</i>. 2006;81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. <i>Clin Infect Dis</i>. 2006;42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis</i>. 2006;43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M, Morin AK. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. <i>Am J Health Syst Pharm</i>. 2007;64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM, Canepa EA. Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. <i>Int J Psychiatry Med</i>. 2008;38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC, Condon F. Serotonin syndrome in an orthopaedic patient secondary to linezolid therapy for MRSA infection. <i>Ir J Med Sci</i>. 2011;180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK, Barber GR. Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. <i>Drug Metabol Drug Interact</i>. 2010;25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG, Lovell EO. Antibiotic-induced serotonin syndrome. <i>J Emerg Med</i>. 2011;40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E, O'Brien D. Serotonin syndrome due to co-administration of linezolid and venlafaxine. <i>J Antimicrob Chemother</i>. 2004;54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. <i>J Clin Psychopharmacol</i>. 2006;26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S, Berman SA. Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. <i>Am J Psychiatry</i>. 2007;164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS, Carpenter EC. Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty. <i>Orthopedics</i>. 2008;31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. <i>J Clin Pharmacol</i>. 2001;41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6521":"<p><b>Title</b> Tricyclic Antidepressants / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, discontinue tricyclic antidepressants (TCAs) prior to administration of linezolid. Waiting at least 2 weeks after TCA discontinuation to initiate linezolid should minimize the interaction risk. If more urgent initiation of linezolid is needed, the availability of alternative agents and interventions should be considered. If the benefit of linezolid under such circumstances outweighs the risk of serotonin toxicity, discontinue the TCA immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last TCA dose, or 24 hours after the last dose of linezolid, whichever comes first. TCA treatment may be resumed 24 hours after the last dose of linezolid. Initiation of a TCA during linezolid treatment is considered contraindicated.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al, “Linezolid and Serotonin Syndrome,” <i>Psychosomatics</i>, 2001, 42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL and Goetz MB, “Serotonin Syndrome and Linezolid,” <i>Clin Infect Dis</i>, 2002, 34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al, “Myelosuppression and Serotonin Syndrome Associated With Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients,” <i>Clin Infect Dis</i>, 2003, 37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N, “Serotonin Syndrome as a Consequence of Drug-Resistant Infections: an Interaction Between Linezolid and Citalopram,” <i>J Am Med Dir Assoc</i>, 2004, 5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al, “Serotonin Syndrome and Linezolid,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M and Perreault S, “Serotonin Toxicity Associated With Concomitant Use of Linezolid,” <i>Ann Pharmacother</i>, 2005, 39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N and Vermette H, “Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine,” <i>Psychosomatics</i>, 2005, 46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al, “Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient,” <i>J Intensive Care Med</i>, 2005, 20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR and Byrd DC, “Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al, “Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise,” <i>Mayo Clin Proc</i>, 2006, 81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M and Gillman PK, “Serotonin Toxicity Associated With the Use of Linezolid: A Review of Postmarketing Data,” <i>Clin Infect Dis</i>, 2006, 42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW and Estes LL, “Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,” <i>Clin Infect Dis</i>, 2006, 43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M and Morin AK, “Mild Serotonin Syndrome Associated With Concurrent Linezolid and Fluoxetine,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM and Canepa EA, “Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases,” <i>Int J Psychiatry Med</i>, 2008, 38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC and Condon F, “Serotonin Syndrome in an Orthopaedic Patient Secondary to Linezolid Therapy for MRSA Infection,” <i>Ir J Med Sci</i>, 2011, 180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK and Barber GR, “Linezolid Interaction With Serotonin Reuptake Inhibitors: Report of Two Cases and Incidence Assessment,” <i>Drug Metabol Drug Interact</i>, 2010, 25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG and Lovell EO, “Antibiotic-Induced Serotonin Syndrome,” <i>J Emerg Med</i>, 2011, 40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E and O'Brien D, “Serotonin Syndrome Due to Co-Administration of Linezolid and Venlafaxine,” <i>J Antimicrob Chemother</i>, 2004, 54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al, “Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine,” <i>J Clin Psychopharmacol</i>, 2006, 26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S and Berman SA, “Serotonin Syndrome Precipitated by the Monoamine Oxidase Inhibitor Linezolid,” <i>Am J Psychiatry</i>, 2007, 164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS and Carpenter EC, “Serotonin Toxicity as a Consequence of Linezolid Use in Revision Hip Arthroplasty,” <i>Orthopedics</i>, 2008, 31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6522":"<p><b>Title</b> Serotonin/Norepinephrine Reuptake Inhibitors / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, discontinue serotonin/norepinephrine reuptake inhibitors (SNRIs) prior to administration of linezolid. Avoid milnacipran within 14 days of stopping linezolid, and avoid linezolid within 5 days of stopping milnacipran. For other SNRIs, waiting at least 5 days (duloxetine) or 7 days (venlafaxine, desvenlafaxine, levomilnacipran) after SNRI discontinuation to initiate linezolid should minimize the interaction risk, but more urgent initiation of linezolid may be considered if the prospective benefits are judged to outweigh the risks in light of any alternatives. When linezolid is initiated under these circumstances, discontinue the SNRI immediately and monitor closely for signs of CNS toxicity for 5 days (duloxetine), 7 days (venlafaxine, desvenlafaxine), or 14 days (levomilnacipran) after the last SNRI dose, or 24 hours after the last dose of linezolid, whichever comes first. SNRI treatment may be resumed 24 hours after the last dose of linezolid. Initiation of an SNRI during linezolid treatment is considered contraindicated.</p>\n<div>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al, “Linezolid and Serotonin Syndrome,” <i>Psychosomatics</i>, 2001, 42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL and Goetz MB, “Serotonin Syndrome and Linezolid,” <i>Clin Infect Dis</i>, 2002, 34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al, “Myelosuppression and Serotonin Syndrome Associated With Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients,” <i>Clin Infect Dis</i>, 2003, 37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N, “Serotonin Syndrome as a Consequence of Drug-Resistant Infections: an Interaction Between Linezolid and Citalopram,” <i>J Am Med Dir Assoc</i>, 2004, 5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al, “Serotonin Syndrome and Linezolid,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M and Perreault S, “Serotonin Toxicity Associated With Concomitant Use of Linezolid,” <i>Ann Pharmacother</i>, 2005, 39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N and Vermette H, “Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine,” <i>Psychosomatics</i>, 2005, 46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al, “Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient,” <i>J Intensive Care Med</i>, 2005, 20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR and Byrd DC, “Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al, “Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise,” <i>Mayo Clin Proc</i>, 2006, 81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M and Gillman PK, “Serotonin Toxicity Associated With the Use of Linezolid: A Review of Postmarketing Data,” <i>Clin Infect Dis</i>, 2006, 42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW and Estes LL, “Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,” <i>Clin Infect Dis</i>, 2006, 43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M and Morin AK, “Mild Serotonin Syndrome Associated With Concurrent Linezolid and Fluoxetine,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM and Canepa EA, “Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases,” <i>Int J Psychiatry Med</i>, 2008, 38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC and Condon F, “Serotonin Syndrome in an Orthopaedic Patient Secondary to Linezolid Therapy for MRSA Infection,” <i>Ir J Med Sci</i>, 2011, 180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK and Barber GR, “Linezolid Interaction With Serotonin Reuptake Inhibitors: Report of Two Cases and Incidence Assessment,” <i>Drug Metabol Drug Interact</i>, 2010, 25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG and Lovell EO, “Antibiotic-Induced Serotonin Syndrome,” <i>J Emerg Med</i>, 2011, 40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E and O'Brien D, “Serotonin Syndrome Due to Co-Administration of Linezolid and Venlafaxine,” <i>J Antimicrob Chemother</i>, 2004, 54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al, “Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine,” <i>J Clin Psychopharmacol</i>, 2006, 26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S and Berman SA, “Serotonin Syndrome Precipitated by the Monoamine Oxidase Inhibitor Linezolid,” <i>Am J Psychiatry</i>, 2007, 164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS and Carpenter EC, “Serotonin Toxicity as a Consequence of Linezolid Use in Revision Hip Arthroplasty,” <i>Orthopedics</i>, 2008, 31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6523":"<p><b>Title</b> Mirtazapine / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Initiation of mirtazapine in a patient receiving linezolid is contraindicated. Consider alternatives to concomitant administration of linezolid with mirtazipine. If a patient who is currently being treated or has recently been treated with mirtazapine must receive linezolid, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia).</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al, “Linezolid and Serotonin Syndrome,” <i>Psychosomatics</i>, 2001, 42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL and Goetz MB, “Serotonin Syndrome and Linezolid,” <i>Clin Infect Dis</i>, 2002, 34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al, “Myelosuppression and Serotonin Syndrome Associated With Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients,” <i>Clin Infect Dis</i>, 2003, 37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N, “Serotonin Syndrome as a Consequence of Drug-Resistant Infections: an Interaction Between Linezolid and Citalopram,” <i>J Am Med Dir Assoc</i>, 2004, 5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al, “Serotonin Syndrome and Linezolid,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M and Perreault S, “Serotonin Toxicity Associated With Concomitant Use of Linezolid,” <i>Ann Pharmacother</i>, 2005, 39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N and Vermette H, “Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine,” <i>Psychosomatics</i>, 2005, 46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al, “Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient,” <i>J Intensive Care Med</i>, 2005, 20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR and Byrd DC, “Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al, “Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise,” <i>Mayo Clin Proc</i>, 2006, 81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M and Gillman PK, “Serotonin Toxicity Associated With the Use of Linezolid: A Review of Postmarketing Data,” <i>Clin Infect Dis</i>, 2006, 42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW and Estes LL, “Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,” <i>Clin Infect Dis</i>, 2006, 43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M and Morin AK, “Mild Serotonin Syndrome Associated With Concurrent Linezolid and Fluoxetine,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM and Canepa EA, “Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases,” <i>Int J Psychiatry Med</i>, 2008, 38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC and Condon F, “Serotonin Syndrome in an Orthopaedic Patient Secondary to Linezolid Therapy for MRSA Infection,” <i>Ir J Med Sci</i>, 2011, 180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK and Barber GR, “Linezolid Interaction With Serotonin Reuptake Inhibitors: Report of Two Cases and Incidence Assessment,” <i>Drug Metabol Drug Interact</i>, 2010, 25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG and Lovell EO, “Antibiotic-Induced Serotonin Syndrome,” <i>J Emerg Med</i>, 2011, 40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E and O'Brien D, “Serotonin Syndrome Due to Co-Administration of Linezolid and Venlafaxine,” <i>J Antimicrob Chemother</i>, 2004, 54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al, “Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine,” <i>J Clin Psychopharmacol</i>, 2006, 26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S and Berman SA, “Serotonin Syndrome Precipitated by the Monoamine Oxidase Inhibitor Linezolid,” <i>Am J Psychiatry</i>, 2007, 164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS and Carpenter EC, “Serotonin Toxicity as a Consequence of Linezolid Use in Revision Hip Arthroplasty,” <i>Orthopedics</i>, 2008, 31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6524":"<p><b>Title</b> TraZODone / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, discontinue trazodone prior to administration of linezolid. Waiting at least 2 weeks after trazodone discontinuation to initiate linezolid should minimize the interaction risk. If more urgent initiation of linezolid is needed, the availability of alternative agents and interventions should be considered. If the benefit of linezolid under such circumstances outweighs the risk of serotonin toxicity, discontinue trazodone immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last trazodone dose, or 24 hours after the last dose of linezolid, whichever comes first. Trazodone treatment may be resumed 24 hours after the last dose of linezolid. Initiation of trazodone during linezolid treatment is considered contraindicated.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to demonstrate such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al, “Linezolid and Serotonin Syndrome,” <i>Psychosomatics</i>, 2001, 42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL and Goetz MB, “Serotonin Syndrome and Linezolid,” <i>Clin Infect Dis</i>, 2002, 34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al, “Myelosuppression and Serotonin Syndrome Associated With Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients,” <i>Clin Infect Dis</i>, 2003, 37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N, “Serotonin Syndrome as a Consequence of Drug-Resistant Infections: an Interaction Between Linezolid and Citalopram,” <i>J Am Med Dir Assoc</i>, 2004, 5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al, “Serotonin Syndrome and Linezolid,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M and Perreault S, “Serotonin Toxicity Associated With Concomitant Use of Linezolid,” <i>Ann Pharmacother</i>, 2005, 39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N and Vermette H, “Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine,” <i>Psychosomatics</i>, 2005, 46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al, “Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient,” <i>J Intensive Care Med</i>, 2005, 20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR and Byrd DC, “Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al, “Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise,” <i>Mayo Clin Proc</i>, 2006, 81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M and Gillman PK, “Serotonin Toxicity Associated With the Use of Linezolid: A Review of Postmarketing Data,” <i>Clin Infect Dis</i>, 2006, 42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW and Estes LL, “Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,” <i>Clin Infect Dis</i>, 2006, 43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M and Morin AK, “Mild Serotonin Syndrome Associated With Concurrent Linezolid and Fluoxetine,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM and Canepa EA, “Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases,” <i>Int J Psychiatry Med</i>, 2008, 38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC and Condon F, “Serotonin Syndrome in an Orthopaedic Patient Secondary to Linezolid Therapy for MRSA Infection,” <i>Ir J Med Sci</i>, 2011, 180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK and Barber GR, “Linezolid Interaction With Serotonin Reuptake Inhibitors: Report of Two Cases and Incidence Assessment,” <i>Drug Metabol Drug Interact</i>, 2010, 25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG and Lovell EO, “Antibiotic-Induced Serotonin Syndrome,” <i>J Emerg Med</i>, 2011, 40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E and O'Brien D, “Serotonin Syndrome Due to Co-Administration of Linezolid and Venlafaxine,” <i>J Antimicrob Chemother</i>, 2004, 54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al, “Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine,” <i>J Clin Psychopharmacol</i>, 2006, 26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S and Berman SA, “Serotonin Syndrome Precipitated by the Monoamine Oxidase Inhibitor Linezolid,” <i>Am J Psychiatry</i>, 2007, 164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS and Carpenter EC, “Serotonin Toxicity as a Consequence of Linezolid Use in Revision Hip Arthroplasty,” <i>Orthopedics</i>, 2008, 31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6525":"<p><b>Title</b> Nefazodone / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Linezolid may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to a risk of serotonin toxicity/serotonin syndrome, discontinue nefazodone prior to administration of linezolid. Waiting at least 2 weeks after nefazodone discontinuation to initiate linezolid should minimize the interaction risk. If more urgent initiation of linezolid is needed, the availability of alternative agents and interventions should be considered. If the benefit of linezolid under such circumstances outweighs the risk of serotonin toxicity, discontinue nefazodone immediately and monitor closely for signs of CNS toxicity for 2 weeks after the last nefazodone dose, or 24 hours after the last dose of linezolid, whichever comes first. Nefazodone treatment may be resumed 24 hours after the last dose of linezolid. Initiation of nefazodone during linezolid treatment is considered contraindicated.</p> \n<p><b>Discussion</b> A number of case reports describe symptoms of serotonin toxicity/serotonin syndrome developing in patients receiving linezolid during or shortly after treatment with drugs that inhibit serotonin reuptake, including selective serotonin reuptake inhibitors (citalopram, escitalopram, fluoxetine, paroxetine, sertraline),<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> tricyclic antidepressants (amitriptyline, imipramine),<sup>12,18</sup> serotonin/norepinephrine reuptake inhibitors (duloxetine, venlafaxine),<sup>7,18,19,20,21,22</sup> mirtazapine,<sup>9,12</sup> and trazodone.<sup>12,13</sup> Additional agents with serotonergic properties, including tramadol, metoclopramide, risperidone, bupropion, lithium, methadone, and fentanyl, were co-prescribed in some of these cases.<sup>12,13,14,20</sup><br><br>According to linezolid prescribing information, symptoms of serotonin toxicity/serotonin syndrome were not described in initial clinical studies with linezolid, nor were such symptoms seen in a clinical study where dextromethorphan (a serotonin reuptake inhibitor) was coadministered with linezolid to healthy volunteers.<sup>23,24</sup> However, because linezolid is a reversible, nonselective inhibitor of monoamine oxidase, its combination with other serotonergic agents could theoretically contribute to development of serotonin toxicity/serotonin syndrome.<sup>23</sup> Given the large number of postmarketing reports that appear to describe such effects clinically, coadministration of linezolid with other serotonergic agents should be undertaken with caution, and patients receiving such therapy should be closely monitored.<sup>23</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lavery S, Ravi H, McDaniel WW, et al, “Linezolid and Serotonin Syndrome,” <i>Psychosomatics</i>, 2001, 42(5):432-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>2. Wigen CL and Goetz MB, “Serotonin Syndrome and Linezolid,” <i>Clin Infect Dis</i>, 2002, 34(12):1651-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>3. Bernard L, Stern R, Lew D, et al, “Serotonin Syndrome After Concomitant Treatment With Linezolid and Citalopram,” <i>Clin Infect Dis</i>, 2003, 36(9):1197. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12715317\">[PubMed 12715317]</a></p>\n<p>4. Hachem RY, Hicks K, Huen A, et al, “Myelosuppression and Serotonin Syndrome Associated With Concurrent Use of Linezolid and Selective Serotonin Reuptake Inhibitors in Bone Marrow Transplant Recipients,” <i>Clin Infect Dis</i>, 2003, 37(1):e8-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12830431\">[PubMed 12830431]</a></p>\n<p>5. Tahir N, “Serotonin Syndrome as a Consequence of Drug-Resistant Infections: an Interaction Between Linezolid and Citalopram,” <i>J Am Med Dir Assoc</i>, 2004, 5(2):111-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984623\">[PubMed 14984623]</a></p>\n<p>6. Thomas CR, Rosenberg M, Blythe V, et al, “Serotonin Syndrome and Linezolid,” <i>J Am Acad Child Adolesc Psychiatry</i>, 2004, 43(7):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15213578\">[PubMed 15213578]</a></p>\n<p>7. Bergeron L, Boule M and Perreault S, “Serotonin Toxicity Associated With Concomitant Use of Linezolid,” <i>Ann Pharmacother</i>, 2005, 39(5):956-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15827071\">[PubMed 15827071]</a></p>\n<p>8. Morales N and Vermette H, “Serotonin Syndrome Associated With Linezolid Treatment After Discontinuation of Fluoxetine,” <i>Psychosomatics</i>, 2005, 46(3):274-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15883150\">[PubMed 15883150]</a></p>\n<p>9. DeBellis RJ, Schaefer OP, Liquori M, et al, “Linezolid-Associated Serotonin Syndrome After Concomitant Treatment With Citalopram and Mirtazepine in a Critically Ill Bone Marrow Transplant Recipient,” <i>J Intensive Care Med</i>, 2005, 20(6):351-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>10. Clark DB, Andrus MR and Byrd DC, “Drug Interactions Between Linezolid and Selective Serotonin Reuptake Inhibitors: Case Report Involving Sertraline and Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(2):269-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>11. Sola CL, Bostwick JM, Hart DA, et al, “Anticipating Potential Linezolid-SSRI Interactions in the General Hospital Setting: An MAOI in Disguise,” <i>Mayo Clin Proc</i>, 2006, 81(3):330-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16529136\">[PubMed 16529136]</a></p>\n<p>12. Lawrence KR, Adra M and Gillman PK, “Serotonin Toxicity Associated With the Use of Linezolid: A Review of Postmarketing Data,” <i>Clin Infect Dis</i>, 2006, 42(11):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p>13. Taylor JJ, Wilson JW and Estes LL, “Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,” <i>Clin Infect Dis</i>, 2006, 43(2):180-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16779744\">[PubMed 16779744]</a></p>\n<p>14. Steinberg M and Morin AK, “Mild Serotonin Syndrome Associated With Concurrent Linezolid and Fluoxetine,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17189581\">[PubMed 17189581]</a></p>\n<p>15. Lorenz RA, Vandenberg AM and Canepa EA, “Serotonergic Antidepressants and Linezolid: A Retrospective Chart Review and Presentation of Cases,” <i>Int J Psychiatry Med</i>, 2008, 38(1):81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18624020\">[PubMed 18624020]</a></p>\n<p>16. McClean M, Walsh JC and Condon F, “Serotonin Syndrome in an Orthopaedic Patient Secondary to Linezolid Therapy for MRSA Infection,” <i>Ir J Med Sci</i>, 2011, 180(1):285-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20886306\">[PubMed 20886306]</a></p>\n<p>17. Go AC, Golightly LK and Barber GR, “Linezolid Interaction With Serotonin Reuptake Inhibitors: Report of Two Cases and Incidence Assessment,” <i>Drug Metabol Drug Interact</i>, 2010, 25(1-4):41-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21417793\">[PubMed 21417793]</a></p>\n<p>18. Miller DG and Lovell EO, “Antibiotic-Induced Serotonin Syndrome,” <i>J Emerg Med</i>, 2011, 40(1):25-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18455905\">[PubMed 18455905]</a></p>\n<p>19. Jones SL, Athan E and O'Brien D, “Serotonin Syndrome Due to Co-Administration of Linezolid and Venlafaxine,” <i>J Antimicrob Chemother</i>, 2004, 54(1):289-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15140859\">[PubMed 15140859]</a></p>\n<p>20. Strouse TB, Kerrihard TN, Forscher CA, et al, “Serotonin Syndrome Precipitated by Linezolid in a Medically Ill Patient on Duloxetine,” <i>J Clin Psychopharmacol</i>, 2006, 26(6):681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17110838\">[PubMed 17110838]</a></p>\n<p>21. Packer S and Berman SA, “Serotonin Syndrome Precipitated by the Monoamine Oxidase Inhibitor Linezolid,” <i>Am J Psychiatry</i>, 2007, 164(2):346-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17267801\">[PubMed 17267801]</a></p>\n<p>22. Mason LW, Randhawa KS and Carpenter EC, “Serotonin Toxicity as a Consequence of Linezolid Use in Revision Hip Arthroplasty,” <i>Orthopedics</i>, 2008, 31(11):1140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226083\">[PubMed 19226083]</a></p>\n<p>23. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>24. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6526":"<p><b>Title</b> Sympathomimetics / Linezolid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Linezolid may enhance the hypertensive effect of Sympathomimetics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available.</p>\n<div>\n <p><b>Sympathomimetics Interacting Members</b> Acebrophylline, Albuterol, Amezinium, Aminophylline, Amphetamine, Arformoterol, Armodafinil, Bambuterol, Benzphetamine, Bitter Orange, Caffeine, Cocaine (Topical), Dexmethylphenidate, Dextroamphetamine, Diethylpropion, DOBUTamine, DOPamine, Doxapram, Dyphylline, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Fenoterol, Formoterol, Indacaterol, Isometheptene, Isoproterenol, Kola Nut, Levalbuterol, Levonordefrin, Lisdexamfetamine, Metaproterenol, Metaraminol, Methamphetamine, Methylphenidate, Midodrine, Modafinil, Naphazoline (Nasal), Naphazoline (Ophthalmic), Norepinephrine, Olodaterol, Oxymetazoline (Nasal), Phendimetrazine, Phentermine, Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Pirbuterol, Propylhexedrine, Pseudoephedrine*, Ritodrine, Salmeterol, Terbutaline, Theophylline, Tulobuterol, Vilanterol, Xylometazoline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in linezolid prescribing information, coadministration of linezolid (600 mg twice daily for 3 days) with pseudoephedrine (60 mg twice, 4 hours apart) or phenylpropanolamine (25 mg twice, 4 hours apart) in healthy volunteers increased the maximum blood pressure elevating effect of those agents by an average of 14 mmHg and 24 mmHg, respectively.<sup>1,2</sup> Peak blood pressure elevations were seen 2-3 hours after administration of pseudoephedrine or phenylpropanolamine, and blood pressure returned to baseline 2-3 hours after peak effect. Heart rate was unaffected with all treatments.<br><br>Linezolid is a reversible, nonselective inhibitor of monoamine oxidase (MAO).<sup>1</sup> Administration of MAO inhibitors can cause accumulation of norepinephrine within adrenergic neurons, including sympathetic neurons that innervate arterial blood vessels. Under such circumstances, the administration of a sympathomimetic agent can cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia and Upjohn Company, June 2010.</p>\n<p>2. Hendershot PE, Antal EJ, Welshman IR, et al, “Linezolid: Pharmacokinetic and Pharmacodynamic Evaluation of Coadministration With Pseudoephedrine HCl, Phenylpropanolamine HCl, and Dextromethorpan HBr,” <i>J Clin Pharmacol</i>, 2001, 41(5):563-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6529":"<p><b>Title</b> Indacaterol / Theophylline Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of indacaterol (e.g., hypokalemia, blood pressure/heart rate elevation) with concomitant use of theophylline derivatives.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline</p>\n</div> \n<p><b>Discussion</b> Prescribing information for indacaterol warns that concomitant treatment with xanthine derivatives may enhance the hypokalemic effects of indacaterol.<sup>1</sup> Increased sympathomimetic effects of the agents (e.g., increases in blood pressure, heart rate) would be expected as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Arcapta (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6530":"<p><b>Title</b> Corticosteroids (Systemic) / Indacaterol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Indacaterol may enhance the hypokalemic effect of Corticosteroids (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for increased potassium-depleting effects of indacaterol with concomitant use of systemic corticosteroids.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Indacaterol prescribing information warns that concomitant treatment with steroids may enhance the hypokalemic effects of indacaterol.<sup>1</sup> Clinically notable decreases in potassium were reported in patients treated with indacaterol in long-term clinical studies, but rates were similar to those seen with placebo.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Arcapta (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6532":"<p><b>Title</b> Dexamethasone (Systemic) / Asparaginase (Erwinia)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Asparaginase (Erwinia) may increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for relatively decreased levels/therapeutic effects of dexamethasone with concomitant use of asparaginase, particularly in patients with higher albumin levels and/or those demonstrating hypersensitivity (including prior sensitivity) to asparaginase. Monitor for increased levels/adverse effects of dexamethasone in patients with lower albumin levels and/or those without hypersensitivity to asparaginase.</p> \n<p><b>Discussion</b> The influence of concurrent asparaginase therapy on dexamethasone pharmacokinetics was studied in pediatric patients (n=214) undergoing treatment for acute lymphoblastic leukemia (ALL).<sup>1</sup> As part of a multi-drug protocol patients were grouped into a low risk treatment arm and received dexamethasone (weeks 1, 4, 7, and 9) and asparaginase (weeks 7, 8, 9) while patients in a high/standard risk treatment arm received dexamethasone (weeks 1, 4, 7, 9) and asparaginase (weeks 1 thru 9). <br><br>Increased dexamethasone clearance was associated with decreased asparaginase exposure (low risk arm), increased albumin levels, and presence of an asparaginase allergy. Decreased dexamethasone clearance was associated with greater asparaginase exposure (standard/high risk arm), decreased albumin levels, and older age. The precise mechanism behind the observed changes in dexamethasone clearance is unknown, but the authors suggest that asparaginase-related hypoalbuminemia may reflect a decrease in hepatic proteins involved in the metabolism of dexamethasone and that lower asparaginase doses/exposure (including presence of allergy, which may lead to greater asparaginase inactivation) may result in less of an effect on hepatic proteins and a relatively greater dexamethasone clearance.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yang L, Panetta JC, Cai X, et al, “Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia,” <i>J Clin Oncol</i> 2008, 26(12): 1932-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18421047\">[PubMed 18421047]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6533":"<p><b>Title</b> Busulfan / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Busulfan. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Due to the risk of seizures with high-dose busulfan treatment, many dosing regimens commonly employ concurrent phenytoin, so pharmacokinetic studies and/or dosing recommendations may somewhat account for this interaction. If this combination is used, monitor patients closely for response to busulfan and monitor busulfan and phenytoin concentrations as appropriate. For seizure prophylaxis that does not use phenytoin (or another enzyme-inducing antiepileptic), note that busulfan clearance may be decreased and busulfan exposure (AUC) may be increased, relative to phenytoin-containing regimens. Monitor such patients closely for evidence of excessive busulfan toxicity.</p> \n<p><b>Discussion</b> In a study comparing busulfan pharmacokinetics after dose 16 with those after dose 1, the busulfan clearance was an average of 19% higher following dose 16 among those who received concurrent phenytoin.<sup>1</sup> Similarly, the average busulfan AUC and half-life were 16.5% and 23% lower, respectively, after dose 16 among those receiving concurrent phenytoin. Of note, 4 of the 7 patients receiving phenytoin experienced continuously decreased busulfan steady-state concentrations. These changes in busulfan pharmacokinetics were not seen a control group (n=10) that received diazepam instead of phenytoin.<br><br>Concurrent phenytoin was found to significantly correlate with the oral clearance of busulfan in another study of patients receiving busulfan prior to a bone marrow transplant.<sup>2</sup> From this analysis, phenytoin use was associated with an approximate 21% increase in busulfan oral clearance. These data are similar to the statement in the busulfan prescribing information that says concurrent phenytoin has been associated with a 15% or greater increase in busulfan clearance.<sup>3,4</sup><br><br>Somewhat in conflict with these other reports, a comparison of busulfan-treated patients receiving clonazepam as seizure prophylaxis (n=24) to patients who had previously receiving phenytoin prophylaxis (n=127) concluded that the average busulfan clearance was non-significantly higher (by approximately 10%) with concurrent clonazepam.<sup>5</sup> Given the enzyme-inducing potential of phenytoin (and no such expected effect with clonazepam), this finding was unexpected and questions the degree to which phenytoin had impacted busulfan clearance in those phenytoin-treated patients.<br><br>The mechanism for this possible interaction is increased busulfan metabolism via the enzyme-inducing effects of phenytoin. Considering the role for glutathione-S-transferase in the metabolism of busulfan, it is suspected that phenytoin induction of this enzyme is primarily responsible for the observed/predicted interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hassan M, Oberg G, Bjorkholm M, et al, “Influence of Prophylactic Anticonvulsant Therapy on High-Dose Busulphan Kinetics,” <i>Cancer Chemother Pharmacol</i>, 1993, 33(3):181-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8269597\">[PubMed 8269597]</a></p>\n<p>2. Sandstrom M, Karlsson MO, Ljungman P, et al, “Population Pharmacokinetic Analysis Resulting in a Tool for Dose Individualization of Busulphan in Bone Marrow Transplantation Recipients,” <i>Bone Marrow Transplant</i>, 2001, 28(7):657-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11704788\">[PubMed 11704788]</a></p>\n<p>3. Prescribing information. Busulfex (busulfan). Rockville, MD: Otsuka America Pharmaceuticals, Inc., April 2011.</p>\n<p>4. Prescribing information. Myleran (busulfan). Research Triangle Park, NC: GlaxoSmithKline, January 2004.</p>\n<p>5. Carreras E, Cahn JY, Puozzo C, et al, “Influence on Busilvex Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data,” <i>Anticancer Res</i>, 2010, 30(7):2977-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20683042\">[PubMed 20683042]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6534":"<p><b>Title</b> Telaprevir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Telaprevir may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of phenytoin (the active metabolite of fosphenytoin) with telaprevir is contraindicated.</p> \n<p><b>Discussion</b> According to the telaprevir prescribing information, the average telaprevir minimum serum concentration (Cmin) and AUC were 68% and 47% lower, respectively, with concurrent use of phenytoin (200 mg every 12 hours for 17 days) and telaprevir (750 mg every 8 hours; n=7).<sup>1</sup> Telaprevir prescribing information lists as contraindicated concurrent therapy with any strong inducers of the CYP3A4 enzyme, including the anticonvulsants carbamazepine, phenytoin, and phenobarbital.<sup>1</sup><br><br>The specific mechanism for this apparent interaction is induction of CYP3A by phenytoin leading to increased telaprevir metabolism and decreased telaprevir serum concentrations.<br><br>Concurrent use of phenytoin and telaprevir also was associated with increased phenytoin concentrations, with the average phenytoin Cmin and AUC increased by 36% and 31%, respectively, with concurrent telaprevir (750 mg every 8 hours; n=7).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Incivek (telaprevir). Cambridge, MA: Vertex Pharmaceuticals Incorporated, 10/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6535":"<p><b>Title</b> Rilpivirine / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of rilpivirine and phenytoin should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Rilpivirine prescribing information lists coadministration with phenytoin as contraindicated due to a risk of decreased rilpivirine concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is phenytoin induction of CYP3A4 mediated rilpivirine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Edurant (rilpivirine). Raritan NJ: Tibotec Therapeutics, May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6536":"<p><b>Title</b> Boceprevir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Boceprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of boceprevir and phenytoin should be avoided due to a possible risk of diminished virologic response.</p> \n<p><b>Discussion</b> Boceprevir prescribing information lists coadministration with phenytoin as contraindicated due to a risk of decreased boceprevir concentrations and loss of virologic response.<sup>1</sup> The presumed primary mechanism of interaction between these agents is phenytoin induction of CYP3A4/5 mediated boceprevir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Victrelis (boceprevir). Whitehouse Station, NJ: Merck &amp; Co., Inc., 5/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6537":"<p><b>Title</b> Phenytoin / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Delavirdine. Delavirdine may increase the serum concentration of Phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of delavirdine and phenytoin due to a potential for diminished virologic response and development of viral resistance.</p> \n<p><b>Discussion</b> According to phenytoin prescribing information, coadministration of phenytoin with delavirdine is contraindicated due to a potential for diminished virologic response and development of viral resistance to delavirdine and other non-nucleoside reverse-transcriptase inhibitors.<sup>1</sup> Delavirdine prescribing information states that phenytoin, phenobarbital, and carbamazepine decreased delavirdine minimum concentrations by 90% based on pharmacokinetic data from clinical studies.<sup>2</sup> The likely primary mechanism of this interaction is phenytoin induction of CYP3A4 mediated delavirdine metabolism. Additionally, delavirdine could theoretically increase phenytoin serum concentrations via inhibition of CYP2C19 mediated phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Prescribing information. Rescriptor (delavirdine). La Jolla, CA: Agouron Pharmaceuticals Inc., May 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6538":"<p><b>Title</b> Acetylcholinesterase Inhibitors / Dipyridamole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dipyridamole may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased pharmacologic effects of acetylcholinesterase inhibitor therapy in patients who are also receiving dipyridamole.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n</div> \n<p><b>Discussion</b> Dipyridamole product labeling warns that concurrent use with acetylcholinesterase inhibitors may antagonize the pharmacologic effects of acetylcholinesterase inhibitor therapy and potentially aggravate conditions such as myasthenia gravis.<sup>1</sup> Dipyridamole inhibits cellular uptake of adenosine. Animal studies have demonstrated that adenosine inhibits the release of acetylcholine <sup>2,3,4</sup> and may contribute to desensitization of the nicotinic acetylcholine receptor.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Persantine (dipyridamole). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., June 2006.</p>\n<p>2. Vizi E.S. and Knoll J., “The Inhibitory Effect Of Adenosine And Related Nucleotides On The Release Of Acetylcholine,” <i>Neuroscience</i>, 1976, 1(5):391-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1004713\">[PubMed 1004713]</a></p>\n<p>3. Searl TJ and Silinsky EM, “Modulation of Calcium-Dependent and -Independent Acetylcholine Release From Motor Nerve Endings,” <i>J Mol Neurosci</i>, 2006, 30(1-2):215-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17192679\">[PubMed 17192679]</a></p>\n<p>4. Giniatullin RA and Sokolova EM, “ATP and Adenosine Inhibit Transmitter Release at the Frog Neuromuscular Junction Through Distinct Presynaptic Receptors,” <i>Br J Pharmacol</i>, 1998, 124(4):839-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9690879\">[PubMed 9690879]</a> </p>\n<p>5. Pitchford S, Day JW, Gordon A, et al, “Nicotinic Acetylcholine Receptor Desensitization Is Regulated by Activation-induced Extracellular Adenosine Accumulation,” <i>J Neurosci</i>, 1992, 12(11):4540-4. [PubMed1331363]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6539":"<p><b>Title</b> Fosphenytoin / Delavirdine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Delavirdine. Delavirdine may increase the serum concentration of Fosphenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of delavirdine and phenytoin due to a potential for diminished virologic response and development of viral resistance.</p> \n<p><b>Discussion</b> According to fosphenytoin prescribing information, coadministration of fosphenytoin with delavirdine is contraindicated due to a potential for diminished virologic response and development of viral resistance to delavirdine and other non-nucleoside reverse-transcriptase inhibitors.<sup>1</sup> Delavirdine prescribing information states that phenytoin, phenobarbital, and carbamazepine decreased delavirdine minimum concentrations by 90% based on pharmacokinetic data from clinical studies.<sup>2</sup> The likely primary mechanism of this interaction is phenytoin induction of CYP3A4 mediated delavirdine metabolism. Additionally, delavirdine could theoretically increase phenytoin serum concentrations via inhibition of CYP2C19 mediated phenytoin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerbyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Prescribing information.Rescriptor (delavirdine). La Jolla, CA: Agouron Pharmaceuticals Inc., May 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6540":"<p><b>Title</b> Phenytoin / Sucralfate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of phenytoin are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Sucralfate may decrease the serum concentration of Phenytoin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In clinical studies of healthy volunteers, simultaneous coadministration of sucralfate with phenytoin decrease phenytoin AUC by approximately 10-20%.<sup>1,2</sup> In another study, steady-state phenytoin serum concentrations were unaffected by sucralfate (1 g four times daily).<sup>3</sup> The most likely mechanism of this interaction is phenytoin binding to sucralfate in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Smart HL, Somerville KW, Williams J, et al, “The Effects of Sucralfate Upon Phenytoin Absorption in Man,” <i>Br J Clin Pharmacol</i>, 1985, 20(3):238-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3840029\">[PubMed 3840029]</a></p>\n<p>2. Hall TG, Cuddy PG, Glass CJ, et al, “Effect of Sucralfate on Phenytoin Bioavailability,” <i>Drug Intell Clin Pharm</i>, 1986, 20(7-8):607-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755676\">[PubMed 3755676]</a></p>\n<p>3. Malli R, Jones WN, Rindone JP, et al, “The Effect of Sucralfate on the Steady-State Serum Concentrations of Phenytoin,” <i>Drug Metabol Drug Interact</i>, 1989, 7(4):287-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2489199\">[PubMed 2489199]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6541":"<p><b>Title</b> Phenytoin / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Nelfinavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin serum concentrations/effects following nelfinavir initiation/dose increase, and increased phenytoin concentrations/effects following nelfinavir discontinuation/dose decrease. Monitor nelfinavir response closely due to the potential for diminished efficacy during phenytoin treatment.</p> \n<p><b>Discussion</b> In a clinical study described in nelfinavir prescribing information, nelfinavir (1,250 mg twice daily for 7 days) decreased phenytoin (300 mg daily for 4 days) AUC, maximum concentration, and minimum concentration by 29%, 21%, and 39%, respectively.<sup>1</sup> Additionally, a published case report describes a patient who experienced decreased (58%) phenytoin concentrations within 3 weeks of initiating nelfinavir (750 mg three times daily).<sup>2</sup> Three months later, the patient experienced a tonic-clonic seizure.<br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., February 2011.</p>\n<p>2. Honda M, Yasuoka A, Aoki M, et al, “A Generalized Seizure Following Initiation of Nelfinavir in a Patient With Human Immunodeficiency Virus Type 1 Infection, Suspected due to Interaction Between Nelfinavir and Phenytoin,” <i>Intern Med</i>, 1999, 38(3):302-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10337948\">[PubMed 10337948]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6542":"<p><b>Title</b> Nelfinavir / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of Nelfinavir. Nelfinavir may decrease the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased phenytoin serum concentrations/effects following nelfinavir initiation/dose increase, and increased phenytoin concentrations/effects following nelfinavir discontinuation/dose decrease. Monitor nelfinavir response closely due to the potential for diminished efficacy during phenytoin treatment.</p> \n<p><b>Discussion</b> In a clinical study described in nelfinavir prescribing information, nelfinavir (1,250 mg twice daily for 7 days) decreased phenytoin (300 mg daily for 4 days) AUC, maximum concentration, and minimum concentration by 29%, 21%, and 39%, respectively.<sup>1</sup> Additionally, a published case report describes a patient who experienced decreased (58%) phenytoin concentrations within 3 weeks of initiating nelfinavir (750 mg three times daily).<sup>2</sup> Three months later, the patient experienced a tonic-clonic seizure.<br><br>The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., February 2011.</p>\n<p>2. Honda M, Yasuoka A, Aoki M, et al, “A Generalized Seizure Following Initiation of Nelfinavir in a Patient With Human Immunodeficiency Virus Type 1 Infection, Suspected due to Interaction Between Nelfinavir and Phenytoin,” <i>Intern Med</i>, 1999, 38(3):302-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10337948\">[PubMed 10337948]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6543":"<p><b>Title</b> Phenytoin / Ethosuximide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ethosuximide may enhance the CNS depressant effect of Phenytoin. Phenytoin may decrease the serum concentration of Ethosuximide. Ethosuximide may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following ethosuximide initiation/dose increase, and decreased concentrations/effects following ethosuximide discontinuation/dose decrease. Additionally, consider monitoring for decreased ethosuximide concentrations/effects and increased CNS depressant effects during concomitant therapy.</p> \n<p><b>Discussion</b> According to both ethosuximide and phenytoin prescribing information, ethosuximide administration can increase serum phenytoin concentrations.<sup>1,2</sup> Two case reports describe children who experienced elevated/higher than expected serum phenytoin concentrations following initiation of ethosuximide.<sup>3,4</sup> However, details of the assays used for phenytoin concentration determination in these cases are not provided, and the presence of ethosuximide has been shown to result in overestimation of phenytoin concentrations with some assays.<sup>5</sup> The mechanism and clinical significance of this possible interaction are unknown.<br><br>In addition to the interaction described above, phenytoin could theoretically decrease ethosuximide serum concentrations via induction of its CYP3A4 mediated metabolism, and the combination of these agents would be expected to result in greater CNS depression than either agent alone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Prescribing information. Zarontin (ethosuximide). New York, MI: Parke-Davis, September 2010.</p>\n<p>3. Dawson GW, Brown HW and Clark BG, “Serum Phenytoin After Ethosuximide,” <i>Ann Neurol</i>, 1978, 4(6):583-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=742866\">[PubMed 742866]</a></p>\n<p>4. Frantzen E, Hansen JM, Hansen OE, et al, “Phenytoin (Dilantin) Intoxication,” <i>Acta Neurol Scand</i>, 1967, 43(4):440-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6081207\">[PubMed 6081207]</a></p>\n<p>5. Kristensen M, Hansen JM, Hansen OE, et al, “Sources of Error in the Determination of Phenytoin (Dilantin) by Svensmark &amp; Kristensen's Method,” <i>Acta Neurol Scand</i>, 1967, 43(4):447-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4170090\">[PubMed 4170090]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6544":"<p><b>Title</b> Fosphenytoin / Ethosuximide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ethosuximide may enhance the CNS depressant effect of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Ethosuximide. Ethosuximide may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following ethosuximide initiation/dose increase, and decreased concentrations/effects following ethosuximide discontinuation/dose decrease. Additionally, consider monitoring for decreased ethosuximide concentrations/effects and increased CNS depressant effects during concomitant therapy.</p> \n<p><b>Discussion</b> According to both ethosuximide and fosphenytoin prescribing information, ethosuximide administration can increase serum phenytoin concentrations.<sup>1,2</sup> Two case reports describe children who experienced elevated/higher than expected serum phenytoin concentrations following initiation of ethosuximide.<sup>3,4</sup> However, details of the assays used for phenytoin concentration determination in these cases are not provided, and the presence of ethosuximide has been shown to result in overestimation of phenytoin concentrations with some assays.<sup>5</sup> The mechanism and clinical significance of this possible interaction are unknown.<br><br>In addition to the interaction described above, phenytoin could theoretically decrease ethosuximide serum concentrations via induction of its CYP3A4 mediated metabolism, and the combination of these agents would be expected to result in greater CNS depression than either agent alone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerebyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Prescribing information. Zarontin (ethosuximide). New York, MI: Parke-Davis, September 2010.</p>\n<p>3. Dawson GW, Brown HW and Clark BG, “Serum Phenytoin After Ethosuximide,” <i>Ann Neurol</i>, 1978, 4(6):583-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=742866\">[PubMed 742866]</a></p>\n<p>4. Frantzen E, Hansen JM, Hansen OE, et al, “Phenytoin (Dilantin) Intoxication,” <i>Acta Neurol Scand</i>, 1967, 43(4):440-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6081207\">[PubMed 6081207]</a></p>\n<p>5. Kristensen M, Hansen JM, Hansen OE, et al, “Sources of Error in the Determination of Phenytoin (Dilantin) by Svensmark &amp; Kristensen's Method,” <i>Acta Neurol Scand</i>, 1967, 43(4):447-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4170090\">[PubMed 4170090]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6545":"<p><b>Title</b> Phenytoin / Halothane</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Halothane may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following halothane administration.</p> \n<p><b>Discussion</b> According to phenytoin prescribing information, administration of halothane with phenytoin has the potential to increase phenytoin serum concentrations.<sup>1</sup> A single published case report describes a child who had a higher than expected serum phenytoin concentration (41 mcg/mL, baseline values not reported for comparison) 72 hours after halothane-based anesthesia.<sup>2</sup> The patient also manifested symptoms of phenytoin toxicity, although these began prior to halothane administration. No further data are available.<br><br>The mechanism of this possible interaction is unknown. The authors of the case report above speculate that elevated phenytoin concentrations may have resulted from acute hepatic injury rather than a specific metabolic interaction, based on elevated transaminase concentrations also observed following halothane administration in the patient.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Karlin JM and Kutt H, “Acute Diphenylhydantoin Intoxication Following Halothane Anesthesia,” <i>J Pediatr</i>, 1970, 76(6):941-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5444592\">[PubMed 5444592]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6546":"<p><b>Title</b> Fosphenytoin / Halothane</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Halothane may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following halothane administration.</p> \n<p><b>Discussion</b> According to fosphenytoin prescribing information, administration of halothane with fosphenytoin has the potential to increase phenytoin serum concentrations.<sup>1</sup> A single published case report describes a child who had a higher than expected serum phenytoin concentration (41 mcg/mL, baseline values not reported for comparison) 72 hours after halothane-based anesthesia.<sup>2</sup> The patient also manifested symptoms of phenytoin toxicity, although these began prior to halothane administration. No further data are available.<br><br>The mechanism of this possible interaction is unknown. The authors of the case report above speculate that elevated phenytoin concentrations may have resulted from acute hepatic injury rather than a specific metabolic interaction, based on elevated transaminase concentrations also observed following halothane administration in the patient.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerebyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Karlin JM and Kutt H, “Acute Diphenylhydantoin Intoxication Following Halothane Anesthesia,” <i>J Pediatr</i>, 1970, 76(6):941-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5444592\">[PubMed 5444592]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6547":"<p><b>Title</b> Phenytoin / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Salicylates may increase the serum concentration of Phenytoin. However, little or no change in free phenytoin concentration is expected. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> Phenytoin prescribing information lists salicylates as a class of drugs that may elevate serum phenytoin concentrations.<sup>1</sup> In clinical investigations, however, salicylates have had either no impact, or a minor impact (maximum 16% increase), on serum free phenytoin concentrations.<sup>2,3,4</sup> Salicylates have the potential to displace phenytoin from protein binding sites,<sup>5,6,7,8</sup> and may thereby cause decreases in total serum phenytoin concentrations,<sup>2,3,4,9</sup> but based on the lack of effect on free phenytoin concentrations these effects are likely of low clinical significance.<br><br>In addition to the impact of salicylates on serum phenytoin concentrations, phenytoin could theoretically decrease the serum concentrations of some salicylates via induction of plasma esterase activity.<sup>10,11</sup> However, the impact of this induction on serum concentrations and effects of salicylates has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Olanow CW, Finn AL and Prussak C, “The Effects of Salicylate on the Pharmacokinetics of Phenytoin,” <i>Neurology</i>, 1981, 31(3):341-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7193826\">[PubMed 7193826]</a></p>\n<p>3. Fraser DG, Ludden TM, Evens RP, et al, “Displacement of Phenytoin From Plasma Binding Sites by Salicylate,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):165-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353334\">[PubMed 7353334]</a></p>\n<p>4. Leonard RF, Knott PJ, Rankin GO, et al, “Phenytoin-Salicylate Interaction,” <i>Clin Pharmacol Ther</i>, 1981, 29(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460475\">[PubMed 7460475]</a></p>\n<p>5. Inoue F and Walsh RJ, “Folate Supplements and Phenytoin-Salicylate Interaction,” <i>Neurology</i>, 1983, 33(1):115-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6681552\">[PubMed 6681552]</a></p>\n<p>6. Lunde PK, Rane A, Yaffe SJ, et al, “Plasma Protein Binding of Diphenylhydantoin in Man. Interaction With Other Drugs and the Effect of Temperature and Plasma Dilution,” <i>Clin Pharmacol Ther</i>, 1970, 11(6):846-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4394754\">[PubMed 4394754]</a></p>\n<p>7. Hooper WD, Sutherland JM, Bochner F, et al, “The Effect of Certain Drugs on the Plasma Protein Binding of Phenytoin,” <i>Aust N Z J Med</i>, 1973, 3(4):377-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4148548\">[PubMed 4148548]</a></p>\n<p>8. Lunde KM, “Plasma Protein Binding of Diphenylhydantoin in Man,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1971, 29 Suppl 3:152-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5316396\">[PubMed 5316396]</a></p>\n<p>9. Paxton JW, “Effects of Aspirin on Salivary and Serum Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):170-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353335\">[PubMed 7353335]</a></p>\n<p>10. Puche E, Garcia de la Serrana H, Mota C, et al, “Serum Aspirin-Esterase Activity in Epileptic Patients Receiving Treatment With Phenobarbital, Phenytoin, Carbamazepine and Valproic Acid,” <i>Int J Clin Pharmacol Res</i>, 1989, 9(1):55-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2496043\">[PubMed 2496043]</a></p>\n<p>11. Puche E, Garcia Morillas M, Garcia de la Serrana H, et al, “Probable Pseudocholinesterase Induction by Valproic Acid, Carbamazepine and Phenytoin Leading to Increased Serum Aspirin-Esterase Activity in Epileptics,” <i>Int J Clin Pharmacol Res</i>, 1989, 9(5):309-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2516508\">[PubMed 2516508]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6548":"<p><b>Title</b> Fosphenytoin / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Salicylates may increase the serum concentration of Fosphenytoin. However, little or no change in free phenytoin concentration is expected. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> Fosphenytoin prescribing information lists salicylates as a class of drugs that may elevate serum phenytoin concentrations.<sup>1</sup> In clinical investigations, however, salicylates have had either no impact, or a minor impact (maximum 16% increase), on serum free phenytoin concentrations.<sup>2,3,4</sup> Salicylates have the potential to displace phenytoin from protein binding sites,<sup>5,6,7,8</sup> and may thereby cause decreases in total serum phenytoin concentrations,<sup>2,3,4,9</sup> but based on the lack of effect on free phenytoin concentrations these effects are likely of low clinical significance.<br><br>In addition to the impact of salicylates on serum phenytoin concentrations, phenytoin could theoretically decrease the serum concentrations of some salicylates via induction of plasma esterase activity.<sup>10,11</sup> However, the impact of this induction on serum concentrations and effects of salicylates has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerebyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Olanow CW, Finn AL and Prussak C, “The Effects of Salicylate on the Pharmacokinetics of Phenytoin,” <i>Neurology</i>, 1981, 31(3):341-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7193826\">[PubMed 7193826]</a></p>\n<p>3. Fraser DG, Ludden TM, Evens RP, et al, “Displacement of Phenytoin From Plasma Binding Sites by Salicylate,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):165-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353334\">[PubMed 7353334]</a></p>\n<p>4. Leonard RF, Knott PJ, Rankin GO, et al, “Phenytoin-Salicylate Interaction,” <i>Clin Pharmacol Ther</i>, 1981, 29(1):56-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7460475\">[PubMed 7460475]</a></p>\n<p>5. Inoue F and Walsh RJ, “Folate Supplements and Phenytoin-Salicylate Interaction,” <i>Neurology</i>, 1983, 33(1):115-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6681552\">[PubMed 6681552]</a></p>\n<p>6. Lunde PK, Rane A, Yaffe SJ, et al, “Plasma Protein Binding of Diphenylhydantoin in Man. Interaction With Other Drugs and the Effect of Temperature and Plasma Dilution,” <i>Clin Pharmacol Ther</i>, 1970, 11(6):846-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4394754\">[PubMed 4394754]</a></p>\n<p>7. Hooper WD, Sutherland JM, Bochner F, et al, “The Effect of Certain Drugs on the Plasma Protein Binding of Phenytoin,” <i>Aust N Z J Med</i>, 1973, 3(4):377-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4148548\">[PubMed 4148548]</a></p>\n<p>8. Lunde KM, “Plasma Protein Binding of Diphenylhydantoin in Man,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1971, 29 Suppl 3:152-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5316396\">[PubMed 5316396]</a></p>\n<p>9. Paxton JW, “Effects of Aspirin on Salivary and Serum Phenytoin Kinetics in Healthy Subjects,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):170-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353335\">[PubMed 7353335]</a></p>\n<p>10. Puche E, Garcia de la Serrana H, Mota C, et al, “Serum Aspirin-Esterase Activity in Epileptic Patients Receiving Treatment With Phenobarbital, Phenytoin, Carbamazepine and Valproic Acid,” <i>Int J Clin Pharmacol Res</i>, 1989, 9(1):55-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2496043\">[PubMed 2496043]</a></p>\n<p>11. Puche E, Garcia Morillas M, Garcia de la Serrana H, et al, “Probable Pseudocholinesterase Induction by Valproic Acid, Carbamazepine and Phenytoin Leading to Increased Serum Aspirin-Esterase Activity in Epileptics,” <i>Int J Clin Pharmacol Res</i>, 1989, 9(5):309-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2516508\">[PubMed 2516508]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6549":"<p><b>Title</b> Phenytoin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Phenytoin. This may be particularly applicable with acute, heavy alcohol consumption. Alcohol (Ethyl) may decrease the serum concentration of Phenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in phenytoin serum concentrations/effects in patients who change alcohol consumption levels, particularly when alcohol consumption is heavy. Moderate alcohol intake in non-alcoholic patients appears to have little impact on phenytoin pharmacokinetics. However, phenytoin and alcohol may have additive or synergistic CNS depressant effects regardless.</p> \n<p><b>Discussion</b> Per phenytoin prescribing information, acute intake of alcohol may increase phenytoin serum concentrations, while chronic intake may decrease concentrations.<sup>1</sup> In a published study of 5 healthy volunteers, ingestion of alcohol (1 g/kg) prior to a single intravenous dose of phenytoin (3 mg/kg) had no impact on phenytoin half-life.<sup>2</sup> Additionally, moderate alcohol intake was not associated with a difference in phenytoin concentration/dose ratio in a study of 210 epileptic patients.<sup>3</sup> However, in a clinical study of chronic alcoholics, withdrawal of alcohol was associated with a 43% increase in phenytoin clearance.<sup>4</sup><br><br>The mechanisms of interaction between phenytoin and alcohol have not been investigated. It has been theorized that heavy alcohol consumption may impair phenytoin clearance, while chronic heavy consumption may induce phenytoin clearance.<sup>4</sup> If this were true, the net effect on phenytoin clearance in chronic alcoholics would be unpredictable and potentially dependent on alcohol consumption levels. For example, in a published case report, increased consumption in a chronic alcoholic may have led to decreased phenytoin concentrations (suggesting that induction may have increased to a greater extent than inhibition).<sup>5</sup><br><br>In addition to the possible changes in phenytoin pharmacokinetics with changes in alcohol consumption patterns, patients receiving phenytoin should be advised that the CNS depressant effects of phenytoin may be enhanced by alcohol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Schmidt D, “Effect of Ethanol Intake on Phenytoin Metabolism in Volunteers,” <i>Experientia</i>, 1975, 31(11):1313-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1204786\">[PubMed 1204786]</a></p>\n<p>3. De Leacy EA, McLeay CD, Eadie MJ, et al, “Effects of Subjects' Sex, and Intake of Tobacco, Alcohol and Oral Contraceptives on Plasma Phenytoin Levels,” <i>Br J Clin Pharmacol</i>, 1979, 8(1):33-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=552294\">[PubMed 552294]</a></p>\n<p>4. Sandor P, Sellers EM, Dumbrell M, et al, “Effect of Short- and Long-Term Alcohol Use on Phenytoin Kinetics in Chronic Alcoholics,” <i>Clin Pharmacol Ther</i>, 1981, 30(3):390-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7273603\">[PubMed 7273603]</a></p>\n<p>5. Bellibas SE and Tuglular I, “A Case of Phenytoin-Alcohol Interaction,” <i>Therapie</i>, 1995, 50(5):487-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8571300\">[PubMed 8571300]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6550":"<p><b>Title</b> Fosphenytoin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Fosphenytoin. Alcohol (Ethyl) may decrease the serum concentration of Fosphenytoin. This may be particularly applicable with chronic, heavy alcohol consumption. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin. This may be particularly applicable with acute, heavy alcohol consumption. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in phenytoin serum concentrations/effects in patients who change alcohol consumption levels, particularly when alcohol consumption is heavy. Moderate alcohol intake in non-alcoholic patients appears to have little impact on phenytoin pharmacokinetics. However, phenytoin and alcohol may have additive or synergistic CNS depressant effects regardless.</p> \n<p><b>Discussion</b> Per fosphenytoin prescribing information, acute intake of alcohol may increase phenytoin serum concentrations, while chronic intake may decrease concentrations.<sup>1</sup> In a published study of 5 healthy volunteers, ingestion of alcohol (1 g/kg) prior to a single intravenous dose of phenytoin (3 mg/kg) had no impact on phenytoin half-life.<sup>2</sup> Additionally, moderate alcohol intake was not associated with a difference in phenytoin concentration/dose ratio in a study of 210 epileptic patients.<sup>3</sup> However, in a clinical study of chronic alcoholics, withdrawal of alcohol was associated with a 43% increase in phenytoin clearance.<sup>4</sup><br><br>The mechanisms of interaction between phenytoin and alcohol have not been investigated. It has been theorized that heavy alcohol consumption may impair phenytoin clearance, while chronic heavy consumption may induce phenytoin clearance.<sup>4</sup> If this were true, the net effect on phenytoin clearance in chronic alcoholics would be unpredictable and potentially dependent on alcohol consumption levels. For example, in a published case report, increased consumption in a chronic alcoholic may have led to decreased phenytoin concentrations (suggesting that induction may have increased to a greater extent than inhibition).<sup>5</sup><br><br>In addition to the possible changes in phenytoin pharmacokinetics with changes in alcohol consumption patterns, patients receiving phenytoin should be advised that the CNS depressant effects of phenytoin may be enhanced by alcohol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerebyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Schmidt D, “Effect of Ethanol Intake on Phenytoin Metabolism in Volunteers,” <i>Experientia</i>, 1975, 31(11):1313-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1204786\">[PubMed 1204786]</a></p>\n<p>3. De Leacy EA, McLeay CD, Eadie MJ, et al, “Effects of Subjects' Sex, and Intake of Tobacco, Alcohol and Oral Contraceptives on Plasma Phenytoin Levels,” <i>Br J Clin Pharmacol</i>, 1979, 8(1):33-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=552294\">[PubMed 552294]</a></p>\n<p>4. Sandor P, Sellers EM, Dumbrell M, et al, “Effect of Short- and Long-Term Alcohol Use on Phenytoin Kinetics in Chronic Alcoholics,” <i>Clin Pharmacol Ther</i>, 1981, 30(3):390-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7273603\">[PubMed 7273603]</a></p>\n<p>5. Bellibas SE and Tuglular I, “A Case of Phenytoin-Alcohol Interaction,” <i>Therapie</i>, 1995, 50(5):487-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8571300\">[PubMed 8571300]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6551":"<p><b>Title</b> TraZODone / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following trazodone initiation/dose increase, or decreased concentrations/effects following trazodone discontinuation/dose decrease. Additionally, monitor for decreased systemic effects of trazodone in patients receiving phenytoin.</p> \n<p><b>Discussion</b> According to phenytoin prescribing information, administration of trazodone with phenytoin may increase phenytoin serum concentrations.<sup>1</sup> In a single published case report, a patient receiving phenytoin with thiothixene was initiated on trazodone (thiothixene was weaned off simultaneously), and within 6 months experienced symptoms of phenytoin toxicity (weakness, dizziness) with serum phenytoin concentration 46 ug/mL.<sup>2</sup> The phenytoin dose was decreased by 1/3, and trazodone dose was decreased from 500 mg/day to 400 mg/day, and serum phenytoin concentrations returned to the 10-20 ug/mL range.<br><br>The mechanism of this possible interaction is unknown and has not been investigated. In addition to the impact of trazodone on phenytoin concentrations, phenytoin could theoretically decrease serum trazodone concentrations via induction of its CYP3A4 mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dilantin (phenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Dorn JM, “A Case of Phenytoin Toxicity Possibly Precipitated by Trazodone,” <i>J Clin Psychiatry</i>, 1986, 47(2):89-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3944071\">[PubMed 3944071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6552":"<p><b>Title</b> TraZODone / Fosphenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosphenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for elevated phenytoin serum concentrations/effects following trazodone initiation/dose increase, or decreased concentrations/effects following trazodone discontinuation/dose decrease. Additionally, monitor for decreased systemic effects of trazodone in patients receiving phenytoin.</p> \n<p><b>Discussion</b> According to fosphenytoin prescribing information, administration of trazodone with phenytoin may increase phenytoin serum concentrations.<sup>1</sup> In a single published case report, a patient receiving phenytoin with thiothixene was initiated on trazodone (thiothixene was weaned off simultaneously), and within 6 months experienced symptoms of phenytoin toxicity (weakness, dizziness) with serum phenytoin concentration 46 ug/mL.<sup>2</sup> The phenytoin dose was decreased by 1/3, and trazodone dose was decreased from 500 mg/day to 400 mg/day, and serum phenytoin concentrations returned to the 10-20 ug/mL range.<br><br>The mechanism of this possible interaction is unknown and has not been investigated. In addition to the impact of trazodone on phenytoin concentrations, phenytoin could theoretically decrease serum trazodone concentrations via induction of its CYP3A4 mediated metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cerebyx (fosphenytoin). New York, NY: Parke-Davis, October 2011.</p>\n<p>2. Dorn JM, “A Case of Phenytoin Toxicity Possibly Precipitated by Trazodone,” <i>J Clin Psychiatry</i>, 1986, 47(2):89-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3944071\">[PubMed 3944071]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6553":"<p><b>Title</b> Ioflupane I 123 / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of amphetamines in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. Although the specific impact of such concurrent use on imaging utility is not known, consider temporarily discontinuing the amphetamine (for 5 half-lives) prior to the ioflupane imaging as clinically appropriate in order to minimize the potentially significant interference. Whether discontinuation of amphetamines prior to ioflupane administration will minimize the interference is not certain.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> Amphetamines bind with high affinity to DAT, and as summarized in a review on the topic, amphetamines may also induce fast internalization of DATs, reducing the number of DATs available for ioflupane binding.<sup>2</sup> It is likely that recent administration of amphetamines may influence the visual assessment of ioflupane scans.<sup>2</sup><br><br>Although the ioflupane prescribing information does not specifically recommend discontinuation of amphetamines prior to imaging,<sup>1</sup> others have recommended temporary discontinuation of amphetamines for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6554":"<p><b>Title</b> Ioflupane I 123 / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of methylphenidate in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. Although the specific impact of such concurrent use on imaging utility is not known, consider temporarily discontinuing methylphenidate (for 5 half-lives) prior to the ioflupane imaging as clinically appropriate in order to minimize the potentially significant interference. Whether discontinuation of methylphenidate prior to ioflupane administration will minimize the interference is not certain.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> Methylphenidate binds with high affinity to DAT, and as summarized in a review on the topic, it is likely that recent administration of methylphenidate may influence the visual assessment of ioflupane scans.<sup>2</sup> Similarly, a study has concluded that a therapeutic dose of methylphenidate decreased striatal ioflupane binding ratios up to 75%.<sup>3</sup><br><br>Although the ioflupane prescribing information does not specifically recommend discontinuation of methylphenidate prior to imaging,<sup>1</sup> others have recommended temporary discontinuation of methylphenidate for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p>3. Vles JS, Feron FJ, Hendriksen JG, et al, “Methylphenidate Down-Regulates the Dopamine Receptor and Transporter System in Children with Attention Deficit Hyperkinetic Disorder (ADHD),” <i>Neuropediatrics</i>, 2003, 34:77-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12776228\">[PubMed 12776228]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6555":"<p><b>Title</b> Ioflupane I 123 / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of dexmethylphenidate in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. Although the specific impact of such concurrent use on imaging utility is not known, consider temporarily discontinuing dexmethylphenidate (for 5 half-lives) prior to the ioflupane imaging as clinically appropriate in order to minimize the potentially significant interference. Whether discontinuation of dexmethylphenidate prior to ioflupane administration will minimize the interference is not certain.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> Methylphenidate and dexmethylphenidate bind with high affinity to DAT, and as summarized in a review on the topic, it is likely that recent administration of methylphenidate may influence the visual assessment of ioflupane scans.<sup>2</sup> Similarly, a study has concluded that a therapeutic dose of methylphenidate decreased striatal ioflupane binding ratios up to 75%.<sup>3</sup><br><br>Although the ioflupane prescribing information does not specifically recommend discontinuation of dexmethylphenidate prior to imaging,<sup>1</sup> others have recommended temporary discontinuation of methylphenidate for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p>3. Vles JS, Feron FJ, Hendriksen JG, et al, “Methylphenidate Down-Regulates the Dopamine Receptor and Transporter System in Children with Attention Deficit Hyperkinetic Disorder (ADHD),” <i>Neuropediatrics</i>, 2003, 34:77-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12776228\">[PubMed 12776228]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6556":"<p><b>Title</b> Ioflupane I 123 / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of a selective serotonin reuptake inhibitor (SSRI) in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of the SSRI prior to ioflupane administration may minimize the interference is unknown.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT, such as the selective serotonin reuptake inhibitors (SSRIs), may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, SSRIs may increase ioflupane binding ratios, but the effect is only around 10% and is not believed to be large enough to cause misinterpretation of a scan.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6557":"<p><b>Title</b> Ioflupane I 123 / Serotonin/Norepinephrine Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Serotonin/Norepinephrine Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of a serotonin/norepinephrine reuptake inhibitor (SNRI) in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of the SNRI prior to ioflupane administration may minimize the interference is unknown.</p>\n<div>\n <p><b>Serotonin/Norepinephrine Reuptake Inhibitors Interacting Members</b> Desvenlafaxine, DULoxetine, Levomilnacipran, Milnacipran, Venlafaxine</p>\n</div> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT, such as the serotonin/norepinephrine reuptake inhibitor (SNRIs), may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, SNRIs may increase ioflupane binding ratios, but the effect is only around 10% and is not believed to be large enough to cause misinterpretation of a scan.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6558":"<p><b>Title</b> Ioflupane I 123 / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BuPROPion may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of bupropion in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. Although the specific impact of such concurrent use on imaging utility is not known, consider temporarily discontinuing bupropion (for 5 half-lives) prior to the ioflupane imaging as clinically appropriate in order to minimize the potentially significant interference. Whether discontinuation of bupropion prior to ioflupane administration will minimize the interference is not certain.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, several reports show that bupropion blocks DATs in vivo, but results are not consistent.<sup>2</sup> Bupropion may be able to decrease the binding of ioflupane to DATs by as much as 20%, possibly interfering with the image.<sup>2</sup><br><br>Although the ioflupane prescribing information does not specifically recommend discontinuation of bupropion prior to imaging,<sup>1</sup> others have recommended temporary discontinuation of bupropion for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6559":"<p><b>Title</b> Ioflupane I 123 / Benztropine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Benztropine may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of benztropine in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. Although the specific impact of such concurrent use on imaging utility is not known, consider temporarily discontinuing benztropine (for 5 half-lives) prior to the ioflupane imaging as clinically appropriate in order to minimize the potentially significant interference. Whether discontinuation of benztropine prior to ioflupane administration will minimize the interference is not certain.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> Benztropine is an anticholinergic that has been shown to have a moderate affinity for DATs.<sup>2</sup> As summarized in a review on the topic, a study examining the benztropine analog difluoropine concluded that the benztropine analog bound up to 76% of DATs in monkeys.<sup>2</sup> Due to the possible effect of benztropine on DATs, concurrent use of benztropine could decrease ioflupane binding ratios and interfere with imaging.<sup>2</sup><br><br>Although the ioflupane prescribing information does not specifically recommend discontinuation of benztropine prior to imaging,<sup>1</sup> others have recommended temporary discontinuation of benztropine for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6560":"<p><b>Title</b> Ioflupane I 123 / FentaNYL</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FentaNYL may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Note that concurrent use of fentanyl in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of such concurrent use on imaging utility is not known. Whether discontinuation of fentanyl prior to ioflupane administration will minimize the interference is not certain, though some authors have recommended temporarily discontinuing fentanyl (for 5 half-lives), as clinically appropriate, prior to the ioflupane imaging in order to minimize the potentially significant interference.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, fentanyl may cause reduced ioflupane binding to DATs and interfere with imaging, although the mechanism is not well understood.<sup>2</sup><br><br>Although the ioflupane prescribing information does not specifically warn about a potential interaction with fentanyl,<sup>1</sup> others have recommended temporary discontinuation of fentanyl for at least 5 half-lives prior to ioflupane administration.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane I 123). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6561":"<p><b>Title</b> Ioflupane I 123 / Selegiline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selegiline may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of selegiline in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of selegiline prior to ioflupane administration may minimize the interference is unknown.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> According to the product label, selegiline has high affinity for DATs and may alter ioflupane binding;<sup>1</sup> however, a review on this subject concluded that selegiline had no effect on DAT binding.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6562":"<p><b>Title</b> Ioflupane I 123 / BusPIRone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> BusPIRone may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of buspirone in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of buspirone prior to ioflupane administration may minimize the interference is unknown.</p> \n<p><b>Discussion</b> According to ioflupane prescribing information, ioflupane binds to the dopamine transporter.<sup>1</sup> Buspirone binds with high affinity to the dopamine transporter and may interfere with the image obtained following administration of ioflupane.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6564":"<p><b>Title</b> Ioflupane I 123 / Norepinephrine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Norepinephrine may diminish the diagnostic effect of Ioflupane I 123. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of norepinephrine in a patient who is to receive imaging with ioflupane I 123 may alter ioflupane binding to the dopamine transporter. The specific impact of this on imaging utility is not known. Whether discontinuation of norepinephrine prior to ioflupane administration may minimize the interference is unknown.</p> \n<p><b>Discussion</b> Ioflupane is a <sup>123</sup>I-labled tracer that binds to the dopamine transporter (DAT), and to a lesser extent the serotonin transporter (SERT).<sup>1,2</sup> Drugs that have an affinity for or otherwise influence the expression of DAT or SERT may interfere with the image obtained following ioflupane administration.<sup>2</sup> As summarized in a review on the topic, high plasma levels of phenylephrine and norepinephrine may change the affinity of radiotracers for DATs.<sup>2</sup> Further studies are needed to determine if adrenergic agonists given at clinical doses affect DAT imaging.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. DaTscan (ioflupane). Arlington Heights, IL: GE Healthcare, Medi-Physics, Inc., April 2011.</p>\n<p>2. Booij J and Kemp P, “Dopamine Transporter Imaging with [123I]FP-CIT SPECT: Potential Effects of Drugs,” <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35:424-38. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17968545\">[PubMed 17968545]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6565":"<p><b>Title</b> Tacrolimus (Systemic) / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor tacrolimus concentrations and clinical response closely following initiation (or dose increase) of concurrent chloramphenicol. Tacrolimus dose reductions are likely to be needed. Similarly, monitor tacrolimus closely following the cessation of chloramphenicol as further tacrolimus dose adjustments may be needed.</p> \n<p><b>Discussion</b> Several case reports describe 130% to 500% increases in serum tacrolimus concentrations with concurrent chloramphenicol.<sup>1,2,3</sup> In one case, an 83% reduction in the tacrolimus dose was needed to maintain therapeutic concentrations.<sup>1</sup> Of note, in the report describing the largest increase in tacrolimus concentration the patient had received an unintentional overdose of chloramphenicol (x 3 days), so whether this magnitude of increase could be observed at standard chloramphenicol doses is uncertain.<sup>2</sup> <br><br>The likely mechanism of this interaction is chloramphenicol-mediated inhibition of tacrolimus metabolism via CYP3A.<sup>3,4,5</sup> An in vitro study using human liver microsomes concluded that chloramphenicol, at clinically relevant concentrations, is a potent inhibitor CYP3A.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schulman SL, Shaw LM, Jabs K, et al, “Interaction Between Tacrolimus and Chloramphenicol in a Renal Transplant Recipient,” <i>Transplantation</i>, 1998, 65:1397-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9625026\">[PubMed 9625026]</a></p>\n<p>2. Taber DJ, Dupuis RE, Hollan KD, et al, “Drug-Drug Interaction Between Chloramphenicol and Tacrolimus in a Liver Transplant Recipient,” <i>Transplant Proc</i>, 2000, 32:660-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10812156\">[PubMed 10812156]</a></p>\n<p>3. Mathis AS, Shah N, Knipp GT, et al, “Interaction of Chloramphenicol and the Calcineurin Inhibitors in Renal Transplant Recipients,” <i>Transpl Infect Dis</i>, 2002, 4(3):169-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12421465\">[PubMed 12421465]</a></p>\n<p>4. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc, September 2011.</p>\n<p>5. Park JY, Kim KA, Kim SL, “Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes,” <i>Antimicrob Agents Chemother</i>, 2003, 47(11):3464-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14576103\">[PubMed 14576103]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6567":"<p><b>Title</b> CycloSPORINE (Systemic) / Chloramphenicol (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloramphenicol (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor cyclosporine concentrations and clinical response closely following initiation (or dose increase) of concurrent chloramphenicol. Cyclosporine dose reductions are likely to be needed. Similarly, monitor cyclosporine closely following the cessation of chloramphenicol as further cyclosporine dose adjustments may be needed.</p> \n<p><b>Discussion</b> Several case reports describe variable increases in serum cyclosporine concentrations following initiation of concurrent chloramphenicol.<sup>1,2,3</sup> Two case reports describe 186% to 850% increases in cyclosporine concentrations despite cyclosporine dose reductions.<sup>1,2</sup> In contrast, a case series (n=3) describes only a 41% maximum increase in cyclosporine concentrations following addition of chloramphenicol.<sup>3</sup><br><br>The likely mechanism of this observed interaction is inhibition of CYP3A-mediated metabolism of cyclosporine by chloramphenicol.<sup>2,3,4,5</sup> An in vitro study using human liver microsomes concluded that chloramphenicol, at clinically relevant concentrations, is a potent inhibitor of CYP3A.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steinfort CL, McConachy KA, “Cyclosporin-Chloramphenicol Drug Interaction in a Heart-Lung Transplant Recipient,” <i>Med J Aust</i>, 1994, 161:455. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7935110\">[PubMed 7935110]</a></p>\n<p>2. Bui L, Huang DD, “Possible Interaction between Cyclosporine and Chloramphenicol,” <i>Ann Pharmacother</i>, 1999, 33:252-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10084427\">[PubMed 10084427]</a></p>\n<p>3. Mathis AS, Shah N, Knipp GT, et al, “Interaction of Chloramphenicol and the Calcineurin Inhibitors in Renal Transplant Recipients,” <i>Transpl Infect Dis</i>, 2002, 4(3):169-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12421465\">[PubMed 12421465]</a></p>\n<p>4. Prescribing information. Gengraf (cyclospirine). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p>5. Park JY, Kim KA, Kim SL, “Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes,” <i>Antimicrob Agents Chemother</i>, 2003, 47(11):3464-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14576103\">[PubMed 14576103]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6569":"<p><b>Title</b> Spironolactone / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the hyperkalemic effect of Spironolactone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium closely if this combination is used. Consider using an alternative to trimethoprim-sulfamethoxazole (TMP-SMZ) when possible, particularly in patients with other risk factors for hyperkalemia (eg, renal dysfunction, older age, use of other drugs or supplements that can increase potassium, use of higher-dose TMP-SMZ, etc.).</p> \n<p><b>Discussion</b> A population-based retrospective study in patients age 66 and older who were receiving the aldosterone antagonist spironolactone and had been hospitalized with hyperkalemia found an increased odds of receiving trimethoprim-sulfamethoxazole (TMP-SMZ) within the prior 14 days [adjusted OR=12.4 (95% CI: 7.1 to 21.6)] versus the comparator antibiotic amoxicillin.<sup>1</sup> When stratified by dose, the risk appeared to be increased with the double strength formulation compared to the single strength (OR = 13.5 vs 9.7).<sup>1</sup> In an additional study by the same group, concomitant administration of spironolactone with TMP-SMZ was shown to be associated with increased odds of sudden death when compared with amoxicillin [adjusted OR=2.5 (1.6 to 3.9)].<sup>2</sup> A case report also describes serious hyperkalemia in a 85-year-old woman who had been treated with TMP-SMZ, spironolactone, and valsartan (an angiotensin II receptor antagonist).<sup>3</sup> Based on this potential interaction between trimethoprim-sulfamethoxazole and spironolactone, trimethoprim-sulfamethoxazole should likely be avoided whenever possible in patients taking spironolactone.<br><br>Hyperkalemia is an established, though often unrecognized, side effect of trimethoprim.<sup>4,5,6,7</sup> Trimethoprim appears to reduce renal potassium excretion, acting similarly to the structurally similar potassium-sparing diuretic amiloride.<sup>6,7</sup> Patients at high risk of developing trimethoprim-induced hyperkalemia appear to include the higher dose trimethoprim, older age, renal insufficiency, use of prednisone, and concurrent use of drugs that can cause or exacerbate hyperkalemia (such as ACEIs, ARBs, aldosterone antagonists, etc.).<sup>8,9,10,11,12,13</sup><br><br>In contrast to these above reports, a nested case-control study of patients using potassium-altering medications concluded that trimethoprim was not a significant risk factor for hyperkalemia.<sup>13</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343:d5228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911446\">[PubMed 21911446]</a></p>\n<p>2. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015; Feb 2 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646289\">[PubMed 25646289]</a></p>\n<p>3. Juvet T, Gourineni VC, Ravi S, Zarich SW. Life-threatening hyperkalemia: a potentially lethal drug combination. <i>Conn Med</i>. 2013;77(8):491-493. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24156179\">[PubMed 24156179]</a></p>\n<p>4. Margassery S, Bastani B. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. <i>J Nephrol</i>. 2001;14(5):410-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11730276\">[PubMed 11730276]</a></p>\n<p>5. Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. <i>Gerontology</i>. 1999;45(4):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10394078\">[PubMed 10394078]</a></p>\n<p>6. Don BR. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects. <i>Clin Nephrol</i>. 2001;55(1):45-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11200867\">[PubMed 11200867]</a></p>\n<p>7. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. <i>Ann Intern Med</i>. 1993;119(4):296-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8328738\">[PubMed 8328738]</a></p>\n<p>8. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585070\">[PubMed 20585070]</a></p>\n<p>9. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. <i>Ann Pharmacother</i>. 2013;47(12):1618-1626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24259630\">[PubMed 24259630]</a></p>\n<p>10. Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. <i>Curr Drug Saf</i>. 2013;8(2):114-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23713542\">[PubMed 23713542]</a></p>\n<p>11. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. <i>Intern Med</i>. 2003;42(8):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12924488\">[PubMed 12924488]</a></p>\n<p>12. Mohan S, Jaitly M, Pogue VA, Cheng JT. Influence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. <i>J Antimicrob Chemother</i>. 2009;64(4):850-852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19656784\">[PubMed 19656784]</a></p>\n<p>13. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. <i>Int J Clin Pharm</i>. 2013;35(6):1099-1104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23974985\">[PubMed 23974985]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6570":"<p><b>Title</b> Eplerenone / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may enhance the hyperkalemic effect of Eplerenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium closely if this combination is used. Consider using an alternative to trimethoprim-sulfamethoxazole (TMP-SMZ) when possible, particularly in patients with other risk factors for hyperkalemia (eg, renal dysfunction, older age, use of other drugs or supplements that can increase potassium, use of higher-dose TMP-SMZ, etc.).</p> \n<p><b>Discussion</b> A population-based retrospective study in patients age 66 and older who were receiving spironolactone, an aldosterone antagonist generally similar to eplerenone, and had been hospitalized with hyperkalemia found an increased odds of receiving trimethoprim-sulfamethoxazole (TMP-SMZ) within the prior 14 days [adjusted OR=12.4 (95% CI: 7.1 to 21.6)] versus the comparator antibiotic amoxicillin.<sup>1</sup> When stratified by dose, the risk appeared to be increased with the double strength formulation compared to the single strength (OR = 13.5 vs 9.7).<sup>1</sup> A case report also describes serious hyperkalemia in a 85-year-old woman who had been treated with TMP-SMZ, spironolactone, and valsartan (an angiotensin II receptor antagonist).<sup>2</sup> Based on this potential interaction between trimethoprim-sulfamethoxazole and spironolactone, trimethoprim-sulfamethoxazole should likely be avoided whenever possible in patients taking spironolactone or similar drugs.<br><br>Hyperkalemia is an established, though often unrecognized, side effect of trimethoprim.<sup>3,4,5,6</sup> Trimethoprim appears to reduce renal potassium excretion, acting similarly to the structurally similar potassium-sparing diuretic amiloride.<sup>5,6</sup> Patients at high risk of developing trimethoprim-induced hyperkalemia appear to include the higher dose trimethoprim, older age, renal insufficiency, use of prednisone, and concurrent use of drugs that can cause or exacerbate hyperkalemia (such as ACEIs, ARBs, aldosterone antagonists, etc.).<sup>7,8,9,10,11</sup><br><br>In contrast to these above reports, a nested case-control study of patients using potassium-altering medications concluded that trimethoprim was not a significant risk factor for hyperkalemia.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343:d5228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911446\">[PubMed 21911446]</a></p>\n<p>2. Juvet T, Gourineni VC, Ravi S, Zarich SW. Life-threatening hyperkalemia: a potentially lethal drug combination. <i>Conn Med</i>. 2013;77(8):491-493. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24156179\">[PubMed 24156179]</a></p>\n<p>3. Margassery S, Bastani B. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment. <i>J Nephrol</i>. 2001;14(5):410-414. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11730276\">[PubMed 11730276]</a></p>\n<p>4. Marinella MA. Trimethoprim-induced hyperkalemia: An analysis of reported cases. <i>Gerontology</i>. 1999;45(4):209-212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10394078\">[PubMed 10394078]</a></p>\n<p>5. Don BR. The effect of trimethoprim on potassium and uric acid metabolism in normal human subjects. <i>Clin Nephrol</i>. 2001;55(1):45-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11200867\">[PubMed 11200867]</a></p>\n<p>6. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. <i>Ann Intern Med</i>. 1993;119(4):296-301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8328738\">[PubMed 8328738]</a></p>\n<p>7. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585070\">[PubMed 20585070]</a></p>\n<p>8. Gentry CA, Nguyen AT. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. <i>Ann Pharmacother</i>. 2013;47(12):1618-1626. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24259630\">[PubMed 24259630]</a></p>\n<p>9. Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. <i>Curr Drug Saf</i>. 2013;8(2):114-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23713542\">[PubMed 23713542]</a></p>\n<p>10. Mori H, Kuroda Y, Imamura S, et al. Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole. <i>Intern Med</i>. 2003;42(8):665-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12924488\">[PubMed 12924488]</a></p>\n<p>11. Mohan S, Jaitly M, Pogue VA, Cheng JT. Influence of concomitant prednisolone on trimethoprim-associated hyperkalaemia. <i>J Antimicrob Chemother</i>. 2009;64(4):850-852. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19656784\">[PubMed 19656784]</a></p>\n<p>12. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. <i>Int J Clin Pharm</i>. 2013;35(6):1099-1104. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23974985\">[PubMed 23974985]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6571":"<p><b>Title</b> Spironolactone / Nitrofurantoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nitrofurantoin may enhance the hyperkalemic effect of Spironolactone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium closely when patients receiving spironolactone are also treated with nitrofurantoin.</p> \n<p><b>Discussion</b> Patients hospitalized with hyperkalemia had more than 2 times the odds [OR=2.4 (95% CI: 1.3 to 4.6)] of having received nitrofurantoin within the last 14 days (than the standard comparator amoxicillin) according to a retrospective population-based study of elderly patients treated with spironolactone.<sup>1</sup> In an additional study by the same group, concomitant administration of spironolactone with nitrofurantoin was shown to be associated with increased odds of sudden death when compared with amoxicillin [adjusted OR=1.7 (1.03 to 2.8)].<sup>2</sup> However, it should be noted that in a sensitivity analysis, which matched patients by disease risk index, nitrofurantoin was found not to be associated with sudden cardiac death [adjusted OR=0.9 (0.4 to 1.9)]. The reason for these discrepant findings is uncertain, but this raises questions regarding the true association between this purported interaction and the risk of sudden death.<br><br>Of note, in two other similar case-control studies of patients receiving chronic treatment with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (ARB), the concurrent use of nitrofurantoin was not associated with any significant increase in the risk of hyperkalemia (OR=0.9 to 1.2) and was associated with a possible decrease in the risk for sudden death [OR=0.64 (0.46 to 0.88)].<sup>3,4</sup> Although these studies were of ACEI/ARB users, that these drugs have some similarity to spironolactone in that they increase hyperkalemia risk and diminish the effects of aldosterone raises some question about the significance of this potential interaction.<br><br>The specific mechanism for this potential interaction is uncertain, though the authors of this report suggest that this may be a result of nitrofurantoin-mediated inhibition of aldosterone synthesis/release.<sup>1</sup> Based on this potential interaction between nitrofurantoin and spironolactone, patients being treated with spironolactone should have their potassium monitored more closely during concurrent treatment with nitrofurantoin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Gomes T, Mamdani MM, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. <i>BMJ</i>. 2011;343:d5228. doi: 10.1136/bmj.d5228. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911446\">[PubMed 21911446]</a></p>\n<p>2. Antoniou T, Hollands S, Macdonald EM, et al. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. <i>CMAJ</i>. 2015; Feb 2 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25646289\">[PubMed 25646289]</a></p>\n<p>3. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. <i>BMJ</i>. 2014;349:g6196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25359996\">[PubMed 25359996]</a></p>\n<p>4. Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20585070\">[PubMed 20585070]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6572":"<p><b>Title</b> Eplerenone / Nitrofurantoin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nitrofurantoin may enhance the hyperkalemic effect of Eplerenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium closely when patients receiving eplerenone are also treated with nitrofurantoin.</p> \n<p><b>Discussion</b> Patients hospitalized with hyperkalemia were more than 2 times as likely to have received nitrofurantoin within the last 14 days (than the standard comparator amoxicillin) according to a retrospective population-based study of elderly patients treated with spironolactone, which, like eplerenone, is an aldosterone antagonist.<sup>1</sup> Based on this potential interaction between nitrofurantoin and spironolactone, patients being treated with spironolactone should have their potassium monitored more closely during concurrent treatment with nitrofurantoin.<br><br>The specific mechanism for this potential interaction is uncertain, though the authors of this report suggest that this may be a result of nitrofurantoin-mediated inhibition of aldosterone synthesis/release.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Antoniou T, Gomes T, Mamdani MM, et al, “Trimethoprim-Sulfamethoxazole Induced Hyperkalaemia in Elderly Patients Receiving Spironolactone: Nested Case-Control Study,” <i>BMJ</i>, 2011, 343:d5228. doi: 10.1136/bmj.d5228 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21911446\">[PubMed 21911446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6573":"<p><b>Title</b> Thyroid Products / Simethicone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered thyroid products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Simethicone may decrease the serum concentration of Thyroid Products. This is likely due to interference with thyroid absorption. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for reduced thyroid product effectiveness if taken simultaneously, and for long peroids of time, with simethicone. To minimize the significance of this potential interaction, separate admininistration of simethicone and thyroid products by as much time as possible.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> According to one case report, an infant receiving levothyroxine experienced a possible drug interaction with simethicone.<sup>1</sup> Despite adequate levothyroxine dosage, thyroid stimulating hormone (TSH) serum concentrations were high. It was discovered the child was being given simethicone drops before feeds, and that no other medications were being administered. Upon discontinuation of the simethicone drops, TSH concentrations normalized, and there was a reduction in the levothyroxine requirement to an age appropriate dose.<sup>1</sup><br><br>The specific mechanism for this drug interaction is uncertain but may be due to the binding of levothyroxine by simethicone, resulting in decreased absorption of levothyroxine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Balapatabendi M, Harris D, Shenoy SD. Drug interaction of levothyroxine with infant colic drops. <i>Arch Dis Child</i>. 2011;96(9):888-889. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21785118\">[PubMed 21785118]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6575":"<p><b>Title</b> CycloSPORINE (Systemic) / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of cyclosporine and any potassium sparing diuretics when possible. When such concurrent use cannot be avoided, monitor potassium concentrations and for any other evidence of hyperkalemia closely.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Cyclosporine prescribing information cautions that cyclosporine should not be used with potassium-sparing diuretics due to the risk for hyperkalemia.<sup>1</sup> Hyperkalemia has been associated with cyclosporine therapy (even apart from any known drug interaction), so it is suspected that concurrent use of any other drug that can increase serum potassium may increase this risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gengraf (cyclospirine). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6576":"<p><b>Title</b> Tacrolimus (Systemic) / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant treatment with tacrolimus and potassium-sparing diuretics due to a possible elevated risk of hyperkalemia.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Tacrolimus prescribing information states that concomitant use with potassium-sparing diuretics should be avoided due to a possible elevated risk of hyperkalemia.<sup>1</sup> In major clinical trials, tacrolimus was associated with mild to severe hyperkalemia in 8% of heart transplant recipients, 31% of kidney transplant recipients, and up to 45% of liver transplant recipients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6577":"<p><b>Title</b> Tacrolimus (Systemic) / Eplerenone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Eplerenone may enhance the hyperkalemic effect of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant treatment with tacrolimus and eplerenone due to a possible elevated risk of hyperkalemia.</p> \n<p><b>Discussion</b> Tacrolimus prescribing information states that concomitant use with agents that can cause hyperkalemia (e.g., eplerenone, which is an aldosterone antagonist) should be avoided due to a possible elevated risk of hyperkalemia.<sup>1</sup> In major clinical trials, tacrolimus was associated with mild to severe hyperkalemia in 8% of heart transplant recipients, 31% of kidney transplant recipients, and up to 45% of liver transplant recipients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prograf (tacrolimus). Deerfield, IL: Astellas Pharma US, Inc., August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6579":"<p><b>Title</b> CycloSPORINE (Systemic) / Eplerenone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Eplerenone may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of cyclosporine and eplerenone when possible. When such concurrent use cannot be avoided, monitor potassium concentrations and for any other evidence of hyperkalemia closely.</p> \n<p><b>Discussion</b> Cyclosporine prescribing information cautions that cyclosporine should not be used with agents that can cause or contribute to hyperkalemia (e.g., eplerenone, which is an aldosterone antagonist) due to the risk for hyperkalemia.<sup>1</sup> Hyperkalemia has been associated with cyclosporine therapy (even apart from any known drug interaction), so it is suspected that concurrent use of any other drug that can increase serum potassium may increase this risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Gengraf (cyclospirine). North Chicago, IL: Abbott Laboratories, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6583":"<p><b>Title</b> Alpha-/Beta-Agonists / Ergot Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ergot Derivatives may enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ergot derivatives with alpha-/beta-agonists, including those used in regional anesthesia, due to a risk of significant blood pressure elevations.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isometheptene, Levonordefrin, Metaraminol, Norepinephrine, Pseudoephedrine</p>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergonovine, Ergotamine, Methylergonovine, Pergolide<br><b>Exceptions</b> Ergoloid Mesylates, Nicergoline</p>\n</div> \n<p><b>Discussion</b> Manufacturer prescribing information and product monographs for several ergot derivatives state that concomitant administration with vasoconstrictors should be avoided due to the potential for significant blood pressure elevations.<sup>1,2,3,4</sup> Several ergot derivatives act as peripheral vasoconstrictors via unknown mechanisms, and are associated with increases in blood pressure independent of concomitant use of other vasoconstrictors.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Ergonovine. Toronto, ON: Alveda Pharmaceuticals Inc., March 2009.</p>\n<p>2. Prescribing information. DHE 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, July 2002.</p>\n<p>3. Prescribing information. Parlodel (bromocriptine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, January 2012.</p>\n<p>4. Prescribing information. Cafergot (ergotamine/caffeine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 3/2006.</p>\n<p>5. Chan KY, Vermeersch S, de Hoon J, et al, “Potential Mechanisms of Prospective Antimigraine Drugs: A Focus on Vascular (Side) Effects,” <i>Pharmacol Ther</i>, 2011, 129(3):332-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21130807\">[PubMed 21130807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6584":"<p><b>Title</b> Methotrexate / SulfaSALAzine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SulfaSALAzine may enhance the hepatotoxic effect of Methotrexate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving both methotrexate and sulfasalazine should receive more intense monitoring for evidence of hepatotoxicity.</p> \n<p><b>Discussion</b> According to methotrexate prescribing information, the risk for hepatotoxicity may be increased when methotrexate is used with other hepatotoxic drugs such as sulfasalazine,<sup>1</sup> which has been associated with a significant number of cases of hepatotoxicity.<sup>2,3,4</sup> Patients receiving such combinations should be monitored more closely for signs/symptoms or other evidence of hepatotoxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Methotrexate. Columbus, OH: Roxane Laboratories, Inc., September 2007.</p>\n<p>2. Aithal GP, “Hepatotoxicity Related to Antirheumatic Drugs,” <i>Nat Rev Rheumatol</i>, 2011, 7(3):139-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21263458\">[PubMed 21263458]</a></p>\n<p>3. Jobanputra P, Amarasena R, Maggs F, et al, “Hepatotoxicity Associated with Sulfasalazine in Inflammatory Arthritis: A Case Series from a Local Surveillance of Serious Adverse Events,” <i>BMC Musculoskelet Disord</i>, 2008, 9:48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18405372\">[PubMed 18405372]</a></p>\n<p>4. Prescribing information. Azulfidine (sulfasalazine). New York, NY: Pfizer Inc, September 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6585":"<p><b>Title</b> Alpha1-Agonists / Ergot Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ergot Derivatives may enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ergot derivatives with alpha1-agonists, including those used in regional anesthesia, due to a risk of substantial blood pressure elevations.</p>\n<div>\n <p><b>Alpha1-Agonists Interacting Members</b> Midodrine, Naphazoline (Nasal), Naphazoline (Ophthalmic), Oxymetazoline (Nasal), Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Propylhexedrine, Xylometazoline</p>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergonovine, Ergotamine, Methylergonovine, Pergolide<br><b>Exceptions</b> Ergoloid Mesylates, Nicergoline</p>\n</div> \n<p><b>Discussion</b> Manufacturer prescribing information and product monographs for several ergot derivatives state that concomitant administration with vasoconstrictors should be avoided due to the potential for significant blood pressure elevations.<sup>1,2,3,4</sup> Several ergot derivatives act as peripheral vasoconstrictors via unknown mechanisms, and are associated with increases in blood pressure independent of concomitant use of other vasoconstrictors.<sup>1,2,3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Ergonovine. Toronto, ON: Alveda Pharmaceuticals Inc., March 2009.</p>\n<p>2. Prescribing information. DHE 45 (dihydroergotamine). Costa Mesa, CA: Valeant Pharmaceuticals North America, July 2002.</p>\n<p>3. Prescribing information. Parlodel (bromocriptine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, January 2012.</p>\n<p>4. Prescribing information. Cafergot (ergotamine/caffeine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 3/2006.</p>\n<p>5. Chan KY, Vermeersch S, de Hoon J, et al, “Potential Mechanisms of Prospective Antimigraine Drugs: A Focus on Vascular (Side) Effects,” <i>Pharmacol Ther</i>, 2011, 129(3):332-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21130807\">[PubMed 21130807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6586":"<p><b>Title</b> Antiarrhythmic Agents (Class III) / Lidocaine (Topical)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor for additive/synergistic pharmacologic effects, and consider electrocardiographic monitoring, when topical lidocaine is used in a patient receiving a class III antiarrhythmic agent.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class III) Interacting Members</b> Amiodarone, Dofetilide, Dronedarone, Ibutilide, Sotalol, Vernakalant</p>\n</div> \n<p><b>Discussion</b> Prescribing information for topical lidocaine cream recommends close monitoring of patients receiving topical lidocaine during treatment with class III antiarrhythmic agents, as transdermally absorbed lidocaine may exert additive or synergistic cardiac effects with these agents.<sup>1</sup><br><br>In addition to the potential for combined pharmacodynamic effects of these agents, the use of amiodarone or dronedarone specifically could slow the rate of lidocaine metabolism via inhibition of its CYP3A4 mediated metabolism. A patient's serum lidocaine concentration was increased to 12.6 mg/L, and he experienced seizure, approximately 65 hours after initiating amiodarone therapy (600 mg twice daily).<sup>2</sup> His serum lidocaine concentration was 5.4 mg/L approximately 12 hours after initiating lidocaine. The pharmacokinetics of lidocaine (1 mg/kg single intravenous dose) were unaltered in 10 patients when administered following a 4- to 5-week course of amiodarone (200-400 mg/day).<sup>3</sup> However, in a study of 6 healthy volunteers, lidocaine (1 mg/kg single intravenous dose) AUC was approximately 20% higher after 6 and 26 days of amiodarone (500 mg orally daily).<sup>4</sup><br><br>Topical lidocaine is absorbed from skin and mucus membranes and may therefore participate in some systemic drug-drug interactions. Absorption is dependent on site of application and increases with concentration, dose, frequency, and duration of use.<sup>1,5,6,7,8</sup> Topical absorption is generally most rapid following intratracheal administration.<sup>6,7,8</sup>. Per Lidoderm (lidocaine patch) prescribing information, healthy volunteers (N=15) applying three 700 mg patches for 12 hours to the back reached an average maximum plasma concentration of 0.13 mg/L.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Emla (lidocaine/prilocaine cream). Wilmington, DE: AstraZeneca LP, April 2006.</p>\n<p>2. Siegmund JB, Wilson JH, and Imhoff TE, “Amiodarone Interaction With Lidocaine,” <i>J Cardiovasc Pharmacol</i>, 1993, 21:513-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7681893\">[PubMed 7681893]</a></p>\n<p>3. Nattel S, Talajic M, Beaudoin D, et al, “Absence of Pharmacokinetic Interaction Between Amiodarone and Lidocaine,” <i>Am J Cardiol</i>, 1994, 73:92-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8279386\">[PubMed 8279386]</a></p>\n<p>4. Ha HR, Candinas R, Stieger B, et al, “Interaction Between Amiodarone and Lidocaine,” <i>J Cardiovasc Pharmacol</i>, 1996, 28(4):533-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8891878\">[PubMed 8891878]</a></p>\n<p>5. Prescribing information. Lidoderm (lidocaine patch). Chadds Ford, PA: Endo Pharmaceuticals, Inc, April 2006.</p>\n<p>6. Prescribing information. Lidocaine viscous (lidocaine hydrochloride solution). Columbus, OH: Roxane Laboratories, Inc, February 2009.</p>\n<p>7. Prescribing information. Xylocaine (lidocaine hydrochloride jelly). Wilmington, DE: AstraZeneca, LP, May 2006.</p>\n<p>8. Prescribing information. Lidocaine ointment. Melville, NY: E Fougera &amp; Co, September 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6587":"<p><b>Title</b> Prilocaine / Methemoglobinemia Associated Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: In infants, avoid lidocaine/prilocaine cream in combination with other agents associated with development of methemoglobinemia.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents.</p>\n<div>\n <p><b>Methemoglobinemia Associated Agents Interacting Members</b> Acetaminophen, Amyl Nitrite, Benzocaine, Celecoxib, Chloroquine, Dapsone (Systemic), Dapsone (Topical), Flutamide, Isosorbide Dinitrate, Isosorbide Mononitrate, Lidocaine (Systemic), Lidocaine (Topical), Mafenide, Metoclopramide, Nicorandil, Nitric Oxide, Nitrofurantoin, Nitroglycerin, Nitroprusside, Phenazopyridine, PHENobarbital, Phenytoin, Prilocaine, Primaquine, Propacetamol, QuiNINE, Sodium Nitrite, SulfADIAZINE, Sulfamethoxazole, SulfaSALAzine, Tetracaine (Topical), Zopiclone</p>\n</div> \n<p><b>Discussion</b> Prescribing information for topical and injectable prilocaine products warns about the potential for development of methemoglobinemia during treatment with prilocaine, either used alone or in combination with other agents associated with methemoglobinemia development.<sup>1,2</sup> The prilocaine metabolite o-toluidine has been shown to produce methemoglobin both in vitro and in vivo,<sup>1</sup> and there are numerous reports of clinically significant methemoglobinemia developing in patients receiving prilocaine.<sup>3,4</sup> Patients at increased risk of clinically significant methemoglobinemia include very young patients, those with glucose-6-phosphate deficiencies, those with congenital or idiopathic methemoglobinemia, and those receiving multiple drugs associated with development of methemoglobinemia.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Citanest plain (prilocaine). York, PA: Dentsply Pharmaceutical, 6/2010.</p>\n<p>2. Prescribing information. Emla (prilocaine/lidocaine). Wilmington, DE: AstraZeneca LP, 4/2006.</p>\n<p>3. Skold A, Cosco DL and Klein R, “Methemoglobinemia: Pathogenesis, Diagnosis, and Management,” <i>South Med J</i>, 2011, 104(11):757-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22024786\">[PubMed 22024786]</a></p>\n<p>4. Mansouri A and Lurie AA, “Concise Review: Methemoglobinemia,” <i>Am J Hematol</i>, 1993, 42(1):7-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8416301\">[PubMed 8416301]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6588":"<p><b>Title</b> Propafenone / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to propafenone closely when starting or stopping concurrent orlistat. Note that abrupt discontinuation of orlistat in patients stable on the combination may result in propafenone toxicity.</p> \n<p><b>Discussion</b> According to propafenone prescribing information, post-marketing reports describe propafenone toxicity (convulsions, atrioventricular (AV) block, and acute circulatory failure) associated with the abrupt discontinuation of orlistat in patients who had previously been stable on that combination.<sup>1</sup><br><br>Although the specific mechanism for this potential interaction is uncertain, it has been suggested that orlistat may limit the absorption of propafenone, resulting in decreased propafenone concentrations. As a result, patients stable on the combination who discontinue orlistat may experience an increase in propafenone absorption and serum concentrations/clinical effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rythmol (propafenone). Research Triangle Park, NC: GlaxoSmithKline, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6590":"<p><b>Title</b> Tacrolimus (Systemic) / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Danazol may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum tacrolimus concentrations during treatment with danazol, and adjust dose as needed.</p> \n<p><b>Discussion</b> Per danazol prescribing information, danazol may increase tacrolimus plasma concentrations and increase the risk of renal toxicity.<sup>1</sup> Additionally, a single published case report describes a patient whose trough tacrolimus (10 mg/day orally) serum concentration increased from 0.4-0.7 ng/mL to 4.9 ng/mL following initiation of danazol (1.2 g/day, then 0.6 g/day).<sup>2</sup><br><br>The mechanism of this interaction is unknown and has not been investigated. Danazol inhibition of CYP3A4 mediated tacrolimus metabolism may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011.</p>\n<p>2. Shapiro R, Venkataramanan R, Warty VS, et al, “FK 506 Interaction With Danazol,” <i>Lancet</i>, 1993, 341(8856):1344-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7684106\">[PubMed 7684106]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6591":"<p><b>Title</b> Tacrolimus (Topical) / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Danazol may increase the serum concentration of Tacrolimus (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring systemic serum tacrolimus concentrations during concomitant treatment with danazol and topical tacrolimus.</p> \n<p><b>Discussion</b> Per danazol prescribing information, danazol may increase tacrolimus plasma concentrations and increase the risk of renal toxicity.<sup>1</sup> Additionally, a single published case report describes a patient whose trough tacrolimus (10 mg/day orally) serum concentration increased from 0.4-0.7 ng/mL to 4.9 ng/mL following initiation of danazol (1.2 g/day, then 0.6 g/day).<sup>2</sup><br><br>The mechanism of this interaction is unknown and has not been investigated. Danazol inhibition of CYP3A4 mediated tacrolimus metabolism may contribute.<br><br>Blood concentrations are generally low (less than 1 ng/mL) when topical tacrolimus ointment is applied as indicated.<sup>3,4,5,6,7,8,9</sup> However, several cases of elevated blood concentrations (with or without systemic toxicity) have been reported with topical tacrolimus.<sup>10,11,12,13,14,15,16,17,18,19,20</sup> Authors have suggested that systemic exposure may increase with larger applied doses, larger treated areas, occlusion, facial or oral application, and application to inflamed or open lesions. The risk for and clinical significance of drug interactions involving topically applied tacrolimus will likely increase in the presence of these factors as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011.</p>\n<p>2. Shapiro R, Venkataramanan R, Warty VS, et al, “FK 506 Interaction With Danazol,” <i>Lancet</i>, 1993, 341(8856):1344-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7684106\">[PubMed 7684106]</a></p>\n<p>3. Prescribing information. Protopic (tacrolimus) . Deerfield, IL: Astellas Pharma US, Inc, January 2009.</p>\n<p>4. Krueger GG, Eichenfield L, Goodman JJ, et al, “Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adult and Pediatric Patients with Moderate to Severe Atopic Dermatits,” <i>J Drugs Dermatol</i>, 2007, 6(2):185-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17373177\">[PubMed 17373177]</a> 5. Draelos Z, Nayak A, Pariser D, et al, “Pharmacokinetics of Topical Calcineurin Inhibitors in Adult Atopic Dermatitis: A Randomized, Investigator-Blind Comparison,” <i>J Am Acad Dermatol</i>, 2005, 53(4):602-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16198779\">[PubMed 16198779]</a></p>\n<p>6. Harper J, Smith C, Rubins A, et al, “A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment After First and Repeated Application to Children With Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 124(4):695-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15816825\">[PubMed 15816825]</a></p>\n<p>7. Undre NA, Moloney FJ, Ahmadi S, et al, “Skin and Systemic Pharmacokinetics of Tacrolimus Following Topical Application of Tacrolimus Ointment in Adults With Moderate to Severe Atopic Dermatitis,” <i>Br J Dermatol</i>, 2009, 160(3):665-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19076975\">[PubMed 19076975]</a></p>\n<p>8. Rubins A, Gutmane R, Valdmane N, et al, “Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults With Moderate to Severe Atopic Dermatitis,” <i>J Invest Dermatol</i>, 2005, 125(1):68-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982304\">[PubMed 15982304]</a></p>\n<p>9. Alaiti S, Kang S, Fiedler C, et al, “Tacrolimus (FK506) Ointment for Atopic Dermatitis: A Phase I Study in Adults and Children,” <i>J Am Acad Dermatol</i>, 1998, 38(1)69-76. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9448208\">[PubMed 9448208]</a></p>\n<p>10. Kameda G, Kramm C Niehues T, et al, “Unexpected High Serum Levels of Tacrolimus After a Single Topical Application in an Infant,” <i>J Pediatr</i>, 2003, 143(4):462. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12970650\">[PubMed 12970650]</a></p>\n<p>11. Ghislain PD, De Decker I, Lachapelle JM, “Efficacy and Systemic Absorption of Topical Tacrolimus Used in Pyoderma Gangrenosum,” <i>Br J Dermatol</i>, 2004, 150(5):1052-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15149540\">[PubMed 15149540]</a></p>\n<p>12. Kawashima M, Nakagawaw H, Ohtsuki M, et al, “Tacrolimus Concentrations in Blood During Topical Treatment of Atopic Dermatitis,” <i>Lancet</i>, 1996, 348(9036):1240-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8898050\">[PubMed 8898050]</a></p>\n<p>13. Allen DM, Esterly NB, “Significant Systemic Absorption of Tacrolimus After Topical Application in a Patient With Lamellar Ichthyosis,” <i>Arch Dermatol</i>, 2002, 138(9):1259-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12225004\">[PubMed 12225004]</a></p>\n<p>14. Allen A, Siegfried E, Silverman R, et al, “Significant Absorption of Topical Tacrolimus in 3 Patients With Netherton Syndrome,” <i>Arch Dermatol</i>, 2001, 137(6)747-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11405764\">[PubMed 11405764]</a></p>\n<p>15. Pitarch G, Torrijos A, Mahiques L, et al, “Systemic Absorption of Topical Tacrolimus in Pyoderma Gangrenosum,” <i>Acta Derm Venereol</i>, 2006, 86(1)64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585995\">[PubMed 16585995]</a></p>\n<p>16. Prot-Labarthe S, Therrien R, Champagne MA, et al, “Toxic Serum Levels of Tacrolimus After Topical Administration in an Infant With Severe Cutaneous Graft-Versus-Host Disease,” <i>Bone Marrow Transplant</i>, 2007, 40(3):295-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17549052\">[PubMed 17549052]</a></p>\n<p>17. Russel RK, Richardson N, Wilson DC, “Systemic Absorption With Complications During Topical Tacrolimus Treatment for Orofactial Crohn Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 2001, 32(2):207-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321395\">[PubMed 11321395]</a></p>\n<p>18. Teshima D, Ikesue H, Itoh Y, et al, “Increased Topical Tacrolimus Absorption in Generalized Leukemic Erythroderma,” <i>Ann Pharmacother</i>, 2003, 37(10):1444-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14519034\">[PubMed 14519034]</a></p>\n<p>19. Beyerler M, Schmid-Grendelmeier P, Hafner J, “Significantly Elevated Systemic Levels After Occlusive Application of Topical Tacrolimus in Atopic Dermatitis,” <i>Dermatology</i>, 2006, 212(3):260-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16549924\">[PubMed 16549924]</a></p>\n<p>20. Conrotto D, Carrozzo M, Ubertalli AV, et al, “Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease,” <i>Transplantation</i>, 2006, 82(8):1113-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060865\">[PubMed 17060865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6592":"<p><b>Title</b> Vitamin D Analogs / Danazol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Danazol may enhance the hypercalcemic effect of Vitamin D Analogs. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for elevated serum calcium concentrations in patients receiving concomitant treatment with vitamin D analogs and danazol.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcitriol (Systemic), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol<br><b>Exceptions</b> Calcipotriene, Calcitriol (Topical), Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Per danazol prescribing information, danazol may increase the hypercalcemic response to vitamin D analogs used in primary hypoparathyroidism.<sup>1</sup> Additionally, a single published case report describes a patient with primary hypoparathyroidism maintained on alfacalcidol (4 mcg/day) whose serum uncorrected calcium increased from 1.6 mM while receiving alfacalcidol alone to a maximum of 4.6 mM, requiring hospital admission, after 9 weeks of treatment with danazol (200 mg twice daily) and calcium lactate gluconate (regimen not specified).<sup>2</sup> Alfacalcidol, danazol, and calcium were stopped for one week and the patient's serum calcium decreased to 3.0 mM. Danazol and alfacalcidol were resumed at the previous doses without calcium supplementation, and the patient's plasma total calcium increased to 4.0 mM over approximately the next month. The patient eventually maintained calcium concentrations around 2.0-2.5 mM with the same danazol dose (200 mg twice daily) but a reduced alfacalcidol dose (0.75 mcg/day).<br><br>The mechanism of this interaction is unknown and has not been investigated.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Danocrine (danazol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, December 2011.</p>\n<p>2. Hepburn NC, Abdul-Aziz LA and Whiteoak R, “Danazol-Induced Hypercalcaemia in Alphacalcidol-Treated Hypoparathyroidism,” <i>Postgrad Med J</i>, 1989, 65(769):849-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2616424\">[PubMed 2616424]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6593":"<p><b>Title</b> Propafenone / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amiodarone may enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of amiodarone with propafenone is not recommended. Consider an alternative to one or both agents.</p> \n<p><b>Discussion</b> According to the propafenone prescribing information, concurrent use of amiodarone may be associated with altered cardiac conduction and repolarization.<sup>1</sup> As a result, concurrent use is not recommended.<sup>1</sup> In addition, both drugs can prolong the QT-interval, meaning that concurrent use may also increase the risk for excessive QT interval prolongation and possible dangerous ventricular arrhythmias.<br><br>As an inhibitor of CYP1A2, amiodarone may also inhibit the metabolism of propafenone, which is partially metabolized by CYP1A2 (though CYP2D6 is primarily responsible).<sup>1</sup> Thus, concurrent amiodarone may also increase propafenone serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rythmol (propafenone). Research Triangle Park, NC: GlaxoSmithKline, June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6594":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / CloBAZam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CloBAZam may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the potential for reduced efficacy of hormonal contraceptives during clobazam treatment, use of an alternative nonhormonal contraceptive is recommended.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Per clobazam prescribing information, the efficacy of hormonal contraceptives may be reduced during treatment with clobazam.<sup>1</sup> Nonhormonal means of contraception are recommended. The presumed mechanism of this interaction is clobazam induction of CYP3A4 mediated metabolism of estrogen and progestin derivatives in hormonal contraceptive products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Onfi (clobazam). Deerfield, IL: Lundbeck Inc., October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6595":"<p><b>Title</b> Progestins (Contraceptive) / CloBAZam</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CloBAZam may decrease the serum concentration of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Due to the potential for reduced efficacy of hormonal contraceptives during clobazam treatment, use of an alternative nonhormonal contraceptive is recommended.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Per clobazam prescribing information, the efficacy of hormonal contraceptives may be reduced during treatment with clobazam.<sup>1</sup> Nonhormonal means of contraception are recommended. The presumed mechanism of this interaction is clobazam induction of CYP3A4 mediated metabolism of estrogen and progestin derivatives in hormonal contraceptive products.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Onfi (clobazam). Deerfield, IL: Lundbeck Inc., October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6596":"<p><b>Title</b> CloBAZam / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of CloBAZam. Alcohol (Ethyl) may increase the serum concentration of CloBAZam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased CNS depression when alcohol is coadministered with clobazam, and caution patients who may consume alcohol about these effects.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, mentioned in clobazam prescribing information, coadministration of alcohol (individually dosed to achieve serum concentrations around 1 mcg/L) with clobazam (20 mg single oral dose) increased clobazam AUC by approximately 55% and caused a trend toward decreased subject performance on a battery of tests measuring reaction time and performance, coordination, body sway, and other variables.<sup>1,2</sup><br><br>The mechanism of pharmacokinetic interaction between these agents is unknown and has not been investigated. The combination of these agents is expected to result in additive CNS depression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Taeuber K, Badian M, Brettel HF, et al, “Kinetic and Dynamic Interaction of Clobazam and Alcohol,” <i>Br J Clin Pharmacol</i>, 1979, 7 Suppl 1:91S-97S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=35214\">[PubMed 35214]</a></p>\n<p>2. Prescribing information. Onfi (clobazam). Deerfield, IL: Lundbeck Inc., October 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6597":"<p><b>Title</b> Pneumococcal Conjugate Vaccine (13-Valent) / Influenza Virus Vaccine (Inactivated)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Age</b>: This interaction appears limited to those patients 50 years of age and older. Patients 65-years-old and older may be at particular risk.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Pneumococcal Conjugate Vaccine (13-Valent) may diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Immune response to these vaccines may be diminished when given concomitantly. This risk appears to exist primarily among patients 50 years of age and older, and those patients 65-years-old or older may be at particular risk. The clinical significance of this interaction is unknown. While separating administration in these patients may yield improved antibody response, there is a risk of patient non-adherence to a return visit for second vaccine administration.</p> \n<p><b>Discussion</b> The proportion of immune responders, which is defined as at least a 4-fold increase in hemagglutination inhibition (HAI) assay titer for trivalent inactivated influenza vaccine (TIV), and the mean IgG responses to individual pneumococcal serotypes for 13-valent pneumococcal conjugate vaccine (PCV13) were both slightly lower with combined administration of both PCV13 and TIV as compared to individual administration of each vaccine in a randomized, controlled trial (n=1,160) of patients 65 years of age and older who had not previously received a pneumococcal vaccine. The PCV13 serotype specific IgG concentrations were immune response were lower overall in the combined PCV13 and TIV group compared to the PCV13 alone group, and statistically significantly lower for 6 individual serotypes. A post-hoc analysis of functional titer antibodies 1 month after vaccination, measured by opsonophagocytic activity (OPA) assays, found that 10 of 13 pneumococcal serotypes met the OPA noninferiority criterion, and OPA titers were lower but not statistically significant for 12 of 13 serotypes in the combined PCV13 and TIV group compared to the PCV13 alone group. The proportion of immune responders to TIV after combined PCV13 and TIV compared to TIV alone were, however, similar for A/H1N1 (80.3% vs. 78.6%, respectively), A/H3N2 (58% vs. 62.6%, respectively), and B (52.2% vs. 54%, respectively).<sup>1,2</sup> The authors concluded that it is difficult to determine the clinical significance of this interaction.<sup>2,3</sup><br><br>Generally similar results were seen in studies of patients 50-59 years of age. In one study (N=1,116), 5 of 13 pneumococcal serotype titers did not meet noninferiority criterion and titers for 10 serotypes were statistically significantly lower with combined administration.<sup>4</sup> According to data in the PCV13 prescribing information, IgG concentrations were noninferior for all 13 serotypes with combined vaccine administration, and functional titers (measured using OPA) were noninferior for 10 of 13 serotypes with combined administration.<sup>2</sup> Immune responses to TIV were consistently noninferior with combined PCV13 and TIV administration.<sup>2,4</sup><br><br>The mechanism and clinical importance of this possible interaction are unknown. The interactions are complex and may be due to multiple factors, including antigen competition and other vaccine components affecting the immune response. A proposed possible mechanism includes vaccine antigens interfering with the MHC class 1 and II antigen processing and presentation pathways, leading to a reduced response to the 13 serotypes in the PCV13 vaccine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwarz TF, Flamaing J, Rumke HC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged 65 years. <i>Vaccine</i>. 2011;29(32):5195-5202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21619909\">[PubMed 21619909]</a></p>\n<p>2. Prevnar 13 (pneumococcal 13-valent conjugate vaccine) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; January 2015.</p>\n<p>3. Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged 65 years. <i>Vaccine</i>. 2013;31(2):291-294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23123107\">[PubMed 23123107]</a></p>\n<p>4. Frenck RW Jr, Gurtman A, Rubino J, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. <i>Clin Vaccine Immunol</i>. 2012;19(8):1296-1303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22739693\">[PubMed 22739693]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6599":"<p><b>Title</b> Propafenone / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP2D6 Inhibitors): Concurrent use of a CYP2D6 inhibitor should be avoided in patients receiving proprafenone and a CYP3A4 inhibitor.</p></li>\n <li><p><b>Genotype</b>: Patients with genetically deficient CYP2D6 activity should avoid this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients more closely for evidence of propafenone toxicity when used together with a strong CYP3A4 inhibitor. Patients using such a combination should avoid the use of any CYP2D6 inhibitor, as the use of propafenone together with both a CYP3A4 inhibitor and a CYP2D6 inhibitor should be avoided due to the potential for an even greater risk for toxicity. Similarly, patients with genetically deficient CYP2D6 activity should avoid concurrent use of propafenone and a CYP3A4 inhibitor due to the potential for a significant increase in toxicity risk.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Concurrent cimetidine (a moderate inhibitor of CYP2D6, CYP3A4, and CYP1A2) was associated with an average 20% increase in propafenone serum concentrations (n=12).<sup>1</sup><br><br>Although CYP2D6, CYP3A4, and CYP1A2 all contribute to the metabolism of propafenone, CYP2D6 is the primary enzyme responsible for propafenone metabolism in most patients.<sup>1</sup> Of note, in patients with impaired CYP2D6 activity (via either genetic factors or drug interactions), the role of CYP3A4 in propafenone metabolism may be increased. As a result, concurrent use of a CYP3A4 inhibitor should be avoided in anyone receiving propafenone who also has impaired CYP2D6 activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rythmol SR (propafenone). Research Triangle Park, NC: GlaxoSmithKline, November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}